

# PLOS ONE

## Hospital admission in patients with type 2 diabetes mellitus in Thailand under the Universal Coverage Scheme: a time- and geographical-trend analysis, 2009–2016 --Manuscript Draft--

|                              |   |
|------------------------------|---|
| <b>Manuscript Number:</b>    | PONE-D-19-26129R1   |
| <b>Article Type:</b>         | Research Article  |
| <b>Full Title:</b>           | Hospital admission in patients with type 2 diabetes mellitus in Thailand under the Universal Coverage Scheme: a time- and geographical-trend analysis, 2009–2016  |
| <b>Short Title:</b>          | Type 2 diabetes mellitus admission in Thailand under the Universal Coverage Scheme  |
| <b>Corresponding Author:</b> | Hisateru Tachimori<br>National Center for Global Health and Medicine<br>Tokyo, JAPAN  |
| <b>Keywords:</b>             | diabetes, type 2 diabetes mellitus, T2DM, DM, Thailand, admission rate, Universal Coverage Scheme, UCS, National Health Security Office, NHSO, non-communicable disease, disease burden   |
| <b>Abstract:</b>             | <p><b>Background</b></p> <p>To estimate the time and geographical trends of nationwide admission rates of type 2 diabetes mellitus (T2DM) and its complications, including chronic kidney disease (CKD), myocardial infarction, cerebrovascular diseases, retinopathy, cataract, and diabetic foot amputation, descriptive analyses of 2009-2016 were performed using the data of the Universal Coverage Scheme (UCS) which covers nearly 70 percent of the Thai population.</p> <p><b>Methods and findings</b></p> <p>The database of T2DM patients aged 15-100 years who were admitted between 2009 and 2016 under the UCS and that of the UCS population were retrieved for the analyses. The admitted cases of T2DM were extracted from the database using disease codes of principal and secondary diagnoses defined by the International Classification of Diseases 9th and 10th Revisions. The T2DM admission rates in 2009-2016 were the number of admissions divided by the number of the UCS population. The standardized admission ratios (SARs) were further estimated in contrast to the expected number of admissions considering age and sex composition of the UCS population in each region.</p> <p>A linearly increased trend was found in T2DM admission rates from 2009 to 2016. Female admission rates were persistently higher than that of males. In 2016, an increase in the T2DM admission rates was observed among the older ages relative to that in 2009. Although the SARs of T2DM were generally higher in Bangkok and central regions in 2009, except that with CKD and foot amputation which had higher trends in northeastern regions, the geographical inequalities were fairly reduced by 2016.</p> <p><b>Conclusion</b></p> <p>Admission rates of T2DM and its major complications increased in Thailand from 2009 to 2016. Although the overall geographical inequalities in the SARs of T2DM were reduced in the country, further efforts are required to improve the health system and policies focusing on risk factors and regions to manage the increasing T2DM</p> |
| <b>Order of Authors:</b>     | <p>Tanapat Laowahutanon</p> <p>Haruyo Nakamura</p> <p>Hisateru Tachimori</p> <p>Shuhei Nomura</p> <p>Tippawan Liabsuetrakul</p> <p>Apiradee Lim</p>   |

|                               |  |
|-------------------------------|--|
|                               | Petch Rawdaree   |
|                               | Netnapis Suchonwanich  |
|                               | Hiroyuki Yamamoto  |
|                               | Kenji Shibuya  |
|                               | Hiroaki Miyata   |
|                               | Virasakdi Chongsuvivatwong   |
| <b>Opposed Reviewers:</b>     |  |
| <b>Response to Reviewers:</b> | <p><b>RESPONSE TO REVIEWERS</b></p> <p>We would like to thank the editor and reviewers for their helpful comments. Our responses to the comments from the editor and reviewers #1, #2 and #3 are given beneath each comment. The revised text is indented and edited in our response for ease of reference, with the section, page numbers and lines of the revised manuscript provided where necessary.</p> <p><b>Response to Reviewer #1</b></p> <p><b>General comments:</b></p> <p>The selection of the patients is unclear and the presentation of the results is not clear either. This paper could have a great potential if presented in relation with incidence and prevalence.</p> <p><b>Major comments:</b></p> <p><b>Abstract</b></p> <p>Some results are only presented in the abstract. For example: "Among the five major diabetic complications, the average annual increase in admission rates in 2009–2016 for CKD, MI, stroke, cataracts, and amputation were 10.8%, 5.6%, 7.7%, 0.2%, and 6.1%, respectively."</p> <p>Thank you very much for pointing this out. We missed reflecting the re-written parts of the main text to the abstract. We have substantially revised the abstract this time. (Abstract, page 3-4)</p> <p><b>Introduction</b></p> <p>Thailand has universal health coverage since 2002. Why your study report results only from 2009?</p> <p>Thank you very much for your observation. Although Thailand achieved UHC in 2002, we decided to use only data from 2009 onwards for our analyses since there were a number of missing values and errors in data before 2009. To make it clearer, we have added the following sentence in Materials and methods section as follows:</p> <p>"Although Thailand achieved UHC in 2002, we decided to use only data from 2009 onwards for our analyses since there were a number of missing values and errors in data before 2009 [13, 14]." (Materials and methods: Data, page 8, lines 17-19)</p> <p>Why only part of the population is covered (69.9%) by the universal health coverage as mentioned in the introduction?</p> <p>Thank you very much for your inquiry. Please see Introduction section (page 5 line 19 to page 6 line 3) where we explained that there are other major health protection schemes in Thailand, i.e. the Civil Service Medical Benefit Scheme and the Social Security Scheme, and the Universal Coverage Scheme (UCS) is the third scheme to cover the rest of the population, so that the country can achieve UHC.</p> <p>I strongly suggest to focus your paper in Thailand globally with prevalence, incidence and mortality if their data allow this kind of analysis and do not focus on the 13 regional offices. Otherwise, can you link the higher prevalence of diabetes observed in some regions to specific risk factors?</p> <p>We appreciate your thoughtful suggestion. Unfortunately, the available data did not allow us to analyse prevalence, incidence and mortality of the whole population in</p> |

Thailand, since our data were limited to people covered by the Universal Coverage Scheme (UCS) in Thailand. However, we have geographically covered Thailand globally as the 13 regions are all regions in the country (see Fig 1).

The last sentence of your introduction about preventive measures is not clear since you are exploring only hospital data and not ambulatory care data.

Thank you very much for your comment. As you pointed it out, we are unable to assess the current practice of preventive measures, as we did not have access to the ambulatory care data. However, we still believe we can discuss the importance of prevention to avoid unnecessary admissions and re-admissions.

#### Methods

The ICD-10 codes selected for CKD are very limited. Why not including E11.2 (Type 2 diabetes mellitus with kidney complications)?

Thank you very much for your concern. We regret it was not very clear, but E11.2 (Type 2 diabetes mellitus with kidney complications) was included in our analyses as we indicated "All admitted cases whose principle and secondary diagnoses were coded as T2DM (E11.1 to E11.9)...," (Materials and methods: Definitions of T2DM and its complications, page 9, line 9-10) meaning that we included E11.1, E11.2, E11.3... E11.9.

Same question with ICD-10 codes N08.3 (Glomerular disorders in diabetes mellitus)?

Again, thank you very much for your suggestion. We have added N08.3 to definition of diabetic complication of chronic kidney disease, as shown below.

"All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9." (Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-11)

Why you did not include I22 (Subsequent myocardial infarction) in the MI category?

Thank you very much for your question. We have added I22 (Subsequent myocardial infarction) in the MI category, as shown below.

"All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), ... MI (I21 and I22)" (Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-11)

Please correct your stroke codes to I60-I69.

Thank you very much for pointing it out. We have corrected the text as follows:

"All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), ... cerebrovascular diseases (I60 to I69)" Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-11 )

Why you used ICD-9 codes for diabetic amputations?

We appreciate your sensible question. We used ICD-9 codes for diabetic amputations in our study because the National Health Security Office in Thailand makes payment based on ICD-9 codes with regards to amputation, and therefore the amputation records were kept based on the ICD-9 codes.

These ICD-9 codes do not seem appropriate. Please clarify their respective definitions. I recommend intervention codes.

Thank you very much for your comment and recommendation. We have carefully reviewed the ICD-9 codes and revised as shown below. Meanwhile, we remained procedure codes of ICD-9 for the above reasons.

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), ... or diabetic foot amputations (8410-8417) were included” Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-13 )

Moreover, did the authors excluded traumatic, cancer, congenital or sepsis related amputations?

Thank you very much for your confirmation. It was rather difficult to exclude traumatic, cancer, congenital or sepsis related amputations with ICD-9 codes. It was the same condition for other types of complications. We indicated this condition as a limitation in our manuscript as follows:

“... and absence of information indicating direct causality between diabetes and complicated conditions were the major limitations of this study.” (Discussion, page 23, lines 11-12)

I would give further details about the definitions of T2DM and complications. As I understand the manuscript, all admission cases were collected for 2009-2016 in which either T2DM and/or a given complication occurs as a primary or secondary reason, for the whole population of the UCS (T2DM or not). Here is my question: Is the presence of T2DM is evaluated using the presence of T2D as a primary or secondary reason for admission OR all prevalent cases of diabetes were included initially before assessing admission? I would clarify this point (otherwise the reader might think the population are not prevalent cases of diabetes).

We appreciate your advice. Our answer to your question is that the presence of T2DM is evaluated using the presence of T2D as a primary or secondary diagnosis (reason) for admission. Although we could not address the prevalent cases in this study, as we could only use the admission data due to the quality reasons, we added further definitions of the T2DM and its complications as shown below. Additionally, we have decided to change some definitions of T2DM and complications, and include retinopathy as the sixth diabetic complication in our study.

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21 and I22), cerebrovascular diseases (I60 to I69), retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8, H25.9, H26.0 to H26.4, H26.8, H26.9, and H28.0), or diabetic foot amputations (8410-8417) were included, and any other cases were excluded from this study. Stage 3 or higher stages of CKD are usually considered as diabetic complications. However, stage 1 and 2 of CKD were also included in this study because the ICD-10 code, E11.2 includes all stages of kidney complications, and thus it was impossible to separate stage 1 and 2 of CKD cases. T2DM cases with acute and subsequent MI were included in this study. While only H36.0, diabetic retinopathy was considered as a diabetic complication, all types of cataract were included as diabetic complications in this study because diabetic cataract is often misdiagnosed as other type of cataract. Diagnosis of foot amputation was considered as a diabetic complication if it was performed from the toe to above the knee.” (Materials and methods: Definitions of T2DM and its complications, page 9, lines 9 to page 10, line 2)

Please specify how data are presented and what they represent for example, in Table 1 (rates, proportions, etc.). In other words, this section should be clarified with addition of specific definition that the authors have misclassified in the results section such as: “The number of admissions refers to how many times the UCS patients were admitted for T2DM with or without complications in each year, whereas the number of patients refers to how many patients were admitted in that year. A patient could be admitted multiple times in a year.”

Thank you very much for your important comment. We have revised the title of Table 1 and added the note underneath Table 1 as follows. We also revised Result section as shown below.

“Table 1. Number and demographic characteristics of the Universal Coverage Scheme patients admitted for type 2 diabetes mellitus in 2009-2016” (Results, page 12-14)

“Note: The Universal Coverage Scheme (UCS) patients admitted for T2DM are the UCS beneficiaries who were admitted for type 2 diabetes mellitus (T2DM) between 2009 and 2016. The number of UCS patients was counted as one in a year. That is, a UCS patient who was admitted for T2DM for multiple times in a year was counted as one in that year. If the same patient was admitted for T2DM in another year, he/she was counted as one again in the separate year.” (Results, page 14)

“Table 1 presents the number and demographic characteristics of the UCS patients admitted for T2DM in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0% of the total population of 2009-2016 in Thailand.” (Results, page 12, lines 2-4)

#### Results

Table 1 is not clear. It seems to be the whole population but the title mentioned with type 2 diabetes. The description of the whole population is not the objective of this paper. Please add units to this corrected Table

Again, thank you very much for your comment. We have revised the title of Table 1 and added the note underneath Table 1 as follows. We also revised Result section as shown below.

“Table 1. Number and demographic characteristics of the Universal Coverage Scheme patients admitted for type 2 diabetes mellitus in 2009-2016” (Results, page 12-14)

“Note: The UCS patients admitted for T2DM are the UCS beneficiaries who were admitted for T2DM between 2009 and 2016. The number of UCS patients was counted as one in a year. That is, a UCS patient who was admitted for T2DM for multiple times in a year was counted as one in that year. If the same patient was admitted for T2DM in another year, he/she was counted as one again in the separate year.” (Results, page 14)

“Table 1 presents the number and demographic characteristics of the UCS patients admitted for T2DM in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0% of the total population of 2009-2016 in Thailand.” (Results, page 12, lines 2-4)

In Figures 2 and 3, please add 95% or 99% confidence intervals.

Thank you very much for your suggestion. We added 95% confidence intervals to Fig 2 and 3 in Results section. In Fig 3, we added the 95% CIs to admission rate, but not to the number of patients and admissions because it makes the figure too busy to add the 95% CIs to all components.

Are rates adjusted in Figure 3?

Thank you for your important inquiry. The rates in Figure 3 were not adjusted. In the Figure 3, we would like to focus on describing temporal trends of crude, i.e. non-adjusted, numbers and rates.

Aside from the Figure 3, we calculated admission rates adjusted by age and sex using the national UCS population of 2009 as the standard to discuss effects of age and sex difference between years in the discussion section.

“While the number of patients, the number of admissions and admission rates of T2DM steadily increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates, which were estimated using the national UCS population of 2009 as the standard population, (12.1 in 2009 and 15.0 in 2016, results not shown) were rather gradual as compared with the numbers of crude admissions rates (12.1 in 2009 and 17.3 in 2016). This result suggests that the increase in the T2DM admission rates is partly due to the increased and aged population of the country.” (Discussion, page 20, lines 1-6)

Please consider confidence intervals for the description of trends and correct this

sentence: "The increasing trend of T2DM admissions with MI and amputation are visually observable." Please add the relative % of increase also.

Thank you very much for your suggestion. We added the 95% CIs to admission rate to Fig 3 in Results section and corrected the related sentences accordingly.

This sentence is repeated twice and should be placed in the Method Section: "The number of admissions refers to how many times the UCS patients were admitted for T2DM with or without complications in each year, whereas the number of patients refers to how many patients were admitted in that year. A patient could be admitted multiple times in a year. The admission rate is the number of admissions divided by the number of the UCS patients in the year, standardized by sex and 15 age categories in 2009."

We are very sorry that it was not clear, but the description in Results section is a note of Figure 3, not part of the main text.

#### Discussion

Do all data from the different regions are collected similarly or there are differences in data collection (missing data)? Similarly, are there important differences in the number of people subscribed on the UCS, differences in resources, etc.? I think these elements could be important to explain the differences inter-regions, if still presented.

Thank you very much for your observation. The data from the different regions were collected similarly. The UCS beneficiaries are those who are not covered by other major health protection schemes, i.e. the Civil Servant Medical Benefit Scheme and the Social Security Scheme and the UCS beneficiaries account for nearly 70 percent of the population. We also did not find inter-regional difference in the number of UCS beneficiaries.

I suggest comparing with additional similar studies in order to discuss your results. I suggest to be careful with assumptions without references, since it might lead to overinterpretation of results.

Thank you so much for your suggestion. We compared with the following additional 9 studies and 2 reports to discuss our studies.

#### Studies

Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the district level and health outcomes: a case study of diabetes mellitus care in Thailand. *Risk Manag Healthc Policy*. 2018; 11, 199-208

Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates and Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage Scheme Data. *AJP Rep*. 2019; 9(4): 328-336.

Sex disparities in diabetes: bridging the gap. *Lancet Diabetes Endocrinol*: Editorial. 2017; 5(11):839

Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S, et al. The Prevalence and Management of Diabetes in Thai Adults. *Diabetes Care*. 2003; 26(10): 2758-2763. DOI: 10.2337/diacare.26.10.2758.

Lindelov M, Hawkins L, Osornprasop S. Government spending and central-local relations in Thailand's health sector. Washington DC: The International Bank for Reconstruction and Developemnt/The World Bank; 2012.

Witthayapipopsakul W, Cetthakrikul N, Suphanchaimat R, Noree T, Sawaengdee K. Equity of health workforce distribution in Thailand: an implication of concentration index. *Risk Manag Healthc Policy*. 2019;12:13-22.

Ruamviboonsuk P, Krause J, Chotcomwongse P, Sayres R, Raman R, Widner K, et al. Deep learning versus human graders for classifying diabetic retinopathy severity in a nationwide screening program. *npj Digit Med*. 2019; 2(25).

Ong-ajyooth L, Vareesangthip K, Khonputsu P, Aekplakorn W. Prevalence of chronic kidney disease in Thai adults: a national health survey. *BMC Nephrol*. 2009; 10(35).

Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupajit K, Panpuwong N, et al. Cost of diabetes and its complications in Thailand: a complete picture of economic burden. *Health Soc Care Community*. 2011; 19(3), 289-298.

#### Reports

Chittinan A, Eiam-ong S, Kantachuvesiri S, Chailimpamontri W. Clinical Practice Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults 2015. 1st ed. Bangkok: The Nephrology Society of Thailand; 2015. [cited 2020 Jan 10]. Available from: [http://www.nephrothai.org/images/10-11-2016/Final\\_%E0%B8%84%E0%B8%A1%E0%B8%AD\\_CKD\\_2015.pdf](http://www.nephrothai.org/images/10-11-2016/Final_%E0%B8%84%E0%B8%A1%E0%B8%AD_CKD_2015.pdf)  
National Statistical Office, Kingdom of Thailand. The 2010 Population and Housing Census. Bangkok: National Statistical Office; 2012.

Do the authors have ideas about what could explain the disparities between males and females?

Thank you very much for your important observation. We added the explanations for the sex disparities as well as a caution to interpret them in Discussion section as follows.

“Biology might play a part in observed sex differences as women typically transition from prediabetes to diabetes with a worse cardiovascular risk profile and a higher BMI than men. However, psychosocial factors, such as health-seeking behavior and provision of health care, play more important part in the differences, which can be addressed through changes in policy and health-care delivery [22]. It should be noted that high admission rate does not necessarily mean high prevalence of the disease, as previous studies showed higher percentage of undiagnosed diabetes [2] and slightly higher fasting plasma glucose among males in Thailand [23]” (Discussion, page 19, lines 11-17)

The authors are writing about HbA1c in prevention of CKD. I think it might be relevant to give more details about this point (for example, what is used in Thailand nowadays and why HbA1c would be better for CKD particularly).

We appreciate your clarification. HbA1c is in fact recommended to be practiced regularly in prevention of CKD among people with diabetes in Thailand, although it has not been fully executed. Therefore, we have revised and added some information to the discussion section as follows.

“To prevent progression of CKD stage, the country should strengthen an effective measure, such as glycated hemoglobin control (HbA1c)  $\leq 7.0\%$  [21], as instructed in the Clinical Practice Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults 2015 [30].” (Discussion, page 21, lines 9-12)

Since diabetes is an ambulatory disease, can the authors give us a sense of the burden in the community in Thailand? If not, please refer to other countries.

Thank you very much for your suggestion. We have added information addressing a sense of burden in the community in Thailand as follows.

“Besides, community involvement in diabetic care should also be carefully monitored, as approximately 77.0% of cost is involved in non-medical activities [36], and community-based screening, study and health promotion would be increasingly important for diabetic care [4].” (Discussion, page 23, lines 15-18)

Minor comments

Introduction

First sentence, please add “in the world.”

Thank you very much for your suggestion. We assume the sentence starting with “globally” describes the situation “in the world”, but we changed “globally” to “in the world” to make the sentence clearer.

P.4, 2nd paragraph: review the units for fasting glucose levels (130/dL).

Thank you very much for correcting it. We have revised the unit from (130/dL) to (130mg/dL).

Methods

I would specify the nature of the study: Retrospective study.

Thank you very much for your suggestion. We have added the word, “retrospective data” in our manuscript as shown below.

“Descriptive analyses using the retrospective data were performed to summarize age, sex and regional structure of the UCS patients who were admitted for T2DM between 2009 and 2016 in Thailand and the trends in 2009 and 2016 were compared to depict the change in the trends over the eight years.” (Materials and methods: Data analysis, page 10, lines 5-7)

Why the approbation of the study was done in Japan?

Thank you very much for your enquiry. This is a study on Thailand, but the approbation was done in Japan because this is a Thai-Japan collaborative study based on the agreements made by the both national organizations.

Results

Please correct everywhere women to females and men to males since you have administrative data and not information about gender.

We appreciate your suggestion. We have corrected all the words “men and women” to “males and females” following your suggestion.

Figure 4 would be easier to understand without the grey lines if you still present regional data.

Thank you for pointing it out. We assume that “the grey lines” you mentioned are the ones shown on the right. These lines appear on some computers, but not all. In fact, we do not see the lines on our computers. We hope the editor has a technical means to solve this problem.

Response to Reviewer #2

General comments:

The authors extract for the universal coverage scheme data all hospitalizations with diabetes listed among the primary or secondary diagnoses (to study admissions caused by diabetes-related complications) in the period 2009-2016. The impressively large and detailed dataset covers over 1.4 million Thai age 15-100 and their 4.2 million admissions for type-2 diabetes (T2DM). They provide descriptive summaries, focusing on admission rates trends nationally and by region, for T2DM and major complications. The results show that standardizing for age and sex reduces the increasing trend in admission rates, suggesting that trends in population growth and aging are important determinants.

Specific comments:

Moreover, the authors speculate that the increase in elderly patients could be explained by greater longevity (i.e. reduced premature mortality) among DM patients. What does a life table for Thailand say about life expectancy conditional on surviving to age 50? 60? Is the growth rate in admissions comparable to the growth rate of survival at those ages? This could provide suggestive evidence confirming or refuting the authors' hypothesis.

We have stated in our manuscript that “the increased trend in T2DM admission rates was rather gradual as compared with the number of patients and admissions.” This means that the increase in the T2DM admission rates was partly influenced by the increased and aged population of the country, while there were also other reasons behind. To avoid this unclarity, we have added values of “sex-and age-adjusted T2DM admission rates”, and changed the word, “largely” to “partly” in the sentence as shown below.

“While the number of patients, the number of admissions and admission rates of T2DM steadily increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates, which were estimated using the national UCS population of 2009 as the standard population, (12.1 in 2009 and 15.0 in 2016, results not shown)



were rather gradual as compared with the numbers of crude admissions rates (12.1 in 2009 and 17.3 in 2016). This result suggests that the increase in the T2DM admission rates is partly due to the increased and aged population of the country. Although further studies are required, it could imply that Thailand may face the greater burden of T2DM in the future if the trend of population growth and aging continues in the country.” (Discussion, page 20, line 1-8)

Of particular note is the high and rising trend in admissions for chronic kidney disease. Unfortunately, the authors do not have any proxies for resource use, but could estimate, based on some estimate of average length of stay and average charges per diem, the associated total spending and out-of-pocket burden. Admittedly that might constitute a separate paper, but it would provide important additional evidence for prioritizing policy to address inequalities of health and access.

Thank you so much for your brilliant suggestion. We'll work on this issue in our next research.

The authors do not discuss gestational diabetes, but that could account for some of the young adult female hospitalizations with diabetes especially as a secondary code and, unless the authors were sure the ICD10/9 codes used excluded them, merit discussion as a sub-category.

Thank you very much for your sensible inquiry. However, we did not include gestational diabetes (ICD-10 code O24) in our study as described in the manuscript (please see below).

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21 and I22), cerebrovascular diseases (I60 to I69), retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8, H25.9, H26.0 to H26.4, H26.8, H26.9, and H28.0), or diabetic foot amputations (8410-8417) were included, and any other cases were excluded from this study.” (Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-14)

What are all the lines coming out of the graphs to the northwest in Figure 4? Fig 4. Comparisons of age- and sex- standardized admission ratios of type 2 diabetes mellitus and its complications in NHSO regions in 2009 and 2016

Thank you very much again. We assume that “the lines coming out of the graphs to the northwest” are the ones shown on the right. These lines appear on some computers, but not all. In fact, we do not see the lines on our computers. We hope the editor has a technical means to solve this problem.

Other explorations of the data that might be meaningful include correlation of the SAR with the % urban residents and/or per capita GDP and/or average years of schooling in each region; reporting and discussing the proportion of admissions in primary, secondary, and tertiary hospitals; at urban versus rural hospitals; at government vs private hospitals; at teaching hospitals vs non-teaching hospitals.

We appreciate your important suggestions. We revised the explanation of the geographical inequalities in Discussion section with the available data, as shown below.

“On the other hand, the persistently high SAR of T2DM with retinopathy in Bangkok is presumably due to high density of specialists as half of 1,500 ophthalmologists, including 200 retinal specialists, practice in Bangkok [33].

The persistently high SAR of T2DM with CKD in northeastern regions was consistent with a previous study and partly attributed to high prevalence of CKD in northeastern regions (10.8%) relative to other regions (north 8.9%, south 8.1% and Bangkok 6.2%) [34], but partly to an association with lower density of physicians and rurality of the region [13]. The density of physicians in northeastern regions is the lowest in the country [32], as low as seven times lower than Bangkok [9]. It is reasonable to assume that in a region where physicians are scarce, T2DM patients with CKD are unlikely to

receive timely, thorough and effective treatment, and consequently deteriorate in conditions. This assumption might explain the high readmission rates of T2DM with CDK, and the highest mortality rates due to diabetes in northeastern regions as found in another study [12]. Moreover, rurality of the northeastern regions, where 71.0% of the population reside in rural setting (north 65.6%, south 66.5% and Central 54.5%) [35], might have halted them from accessing adequate primary care. A previous study found a strong association between the high SAR of diabetes and rurality as the rural population tends to have lack of public transport alternatives and poor health literacy with less education which often limit accessibility to health care. The study also suggested that the percentage of patients who had received up to secondary education was lower in rural districts by approximately 10% [13].” (Discussions, page 22 line 10 to page 23, line 9)

To make the analyses comparable internationally and to allow even more precision in benchmarking the Thai national and regional trends in DM admissions, the authors could calculate the DM avoidable admissions rate as used in OECD metrics for the quality of primary care. This would simply involve standardizing to a comparable population, such as what the OECD does: rates per 100 000 population, age-sex standardized to the 2010 OECD population aged 15 and over (see references below). It would also provide an internationally comparable metric for benchmarking the Thai primary care system for DM management with other health systems, over the study period and as a baseline for tracking further improvements into the future. Of course, the authors may not be able to apply the full inclusion and exclusion criteria, so it would only be suggestive. For example, it does not seem that the authors can categorize the admissions according to whether or not the patient died during the admission. They may not be able to exclude those transferred from another hospital, although the date(s) of admission would be suggestive for creating that categorization from the raw admissions data. Again, estimating DM avoidable admissions rates could constitute a separate paper, but since it draws on exactly the kind of data the authors summarize in this paper, I would urge the authors to consider including this and thus able to attract a wider readership and evidence for policy top address the important trends they highlight.

We appreciate your sensible suggestion. We'll work on these in our next research.

#### Response to Reviewer #3

##### General comments:

This is an interesting manuscript providing the big picture of type 2 diabetes in the Thailand population between 2009-2016. I appreciated the reading and the figures are well-chosen. The authors conclude to an increase in type 2 diabetes over time. There may be a need for improved health care system/policies/services/prevention for this population. Even though I appreciated the paper, I would have some questions for the authors.

##### Major comments

Aren't there any paper published with those databases to support what the authors claim in the data section of the Method?

Thank you very much for your inquiry. As you suggested, we have included the following reference papers to support our decision to use only the data of 2009 and onwards in Materials and methods: Data section.

Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the district level and health outcomes: a case study of diabetes mellitus care in Thailand. *Risk Manag Healthc Policy*. 2018; 11, 199-208

Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates and Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage Scheme Data. *AJP Rep*. 2019; 9(4): 328-336.

Definitions of T2DM: where was diabetic amputation (only) defined based on the ICD 9 coding (paralele database?)?

We appreciate your concern. Diabetic amputation defined based on ICD-9 codes was a parallel database, “the operation database,” as described below, but the operation

database also belongs to the National Health Security Office.

“Two are reports sent from hospitals to the Ministry of Public Health, namely the hospital admission database and the operation database...” (Materials and methods: Data, page 8, lines 3-5)

I think there is a typo for the stroke definition (I60 to I69 and not I6.0 to I6.9). Furthermore, if those are really the codes used, it does not only refer to stroke but rather largely to cerebrovascular diseases.

Thank you very much for pointing it out. We have corrected the text as follows:

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9) ...cerebrovascular diseases (I60 to I69), ...” (Materials and methods: Definitions of T2DM and its complications, page 9, lines 9-11)

According to your suggestion, we also corrected the word “stroke” to “cerebrovascular diseases.”

Diabetic amputations codes selection (ICD9 8401-8415) would need a reference or more explanations for rational.

We appreciate your suggestion. We have carefully reviewed ICD-9 codes again and slightly changed the codes included this study and revised the text as follows.

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), with or without ... or diabetic foot amputations (8410-8417) were included ... Diagnosis of foot amputation was considered as a diabetic complication if it was performed from the toe to above the knee.” (Materials and methods: Definitions of T2DM and its complications, page 9, line 9 to page 10, line 2 )

Data analysis: the authors should explain how were the 2009-2016 trends compared (visually I think).

Thank you very much for your important suggestion. Please see Fig. 3 that explains the 2009-2016 trends visually.

The results would benefit from a more sophisticated trend analysis, using for example a binomial regression model to obtain the precise slope % and a contrast test to compare in sub-analyses. Even though different, this paper and its references may help: Leclerc J et al. Circulation: Cardiovascular Quality and Outcomes, 2017.

We very much appreciated your proposal with the useful reference for a more sophisticated trend analysis. We have conducted time series regressions with the following negative binomial regression model, and added the methods and results to our manuscript as shown below.

“To estimate temporal trend of admissions, we conducted time series regressions with the following negative binomial regression model.

$n_i \sim \text{NegativeBinomial}(\mu_i, \phi)$

$\mu_i = \exp(\beta_0 + \beta_1 x + \log [N_i])$

where  $n_i$  is the number of admissions of  $i$ th time point,  $N_i$  is the number of UC population of  $i$ th time point,  $x$  is the indicator variable of time points,  $\mu$  is the mean parameter and  $\phi$  is dispersion parameter of Negative Binomial distribution,  $\beta_0$  is the intercept, and  $\beta_1$  is the slope parameter.” (Materials and methods: Data analyses, page 11, line 1 - 5 )

“Table 2 presents the results of the time series regressions to estimate temporal trend of admissions showed that all types of T2DM admissions except that with cataract had a significant and positive temporal trend.

Table 2. Time series regressions parameters of temporal trend analysis for admissions  
Parameters Estimate SE z value p value

All DM admissions

$\beta_0$ : intercept -4.4605290.006002-743.16p < 0.001

$\beta_1$ : time point 0.0505660.00118742.61 p < 0.001  
 DM with CKD admissions  
 $\beta_0$ : intercept -6.1083890.009446-646.64 p < 0.001  
 $\beta_1$ : time point 0.0956750.001861 51.41 p < 0.001  
 DM with MI admissions  
 $\beta_0$ : intercept -8.115380.02155-376.58 p < 0.001  
 $\beta_1$ : time point 0.075410.0042417.78 p < 0.001  
 DM with cerebrovascular diseases admissions  
 $\beta_0$ : intercept -7.2516870.009935-729.93 p < 0.001  
 $\beta_1$ : time point 0.0843580.00194143.47 p < 0.001  
 DM with cataract admissions  
 $\beta_0$ : intercept -7.604557 0.046891-162.175 p < 0.001  
 $\beta_1$ : time point 0.0152440.0092831.6420.101  
 DM with retinopathy admissions  
 $\beta_0$ : intercept -8.9410960.028458-314.181 p < 0.001  
 $\beta_1$ : time point 0.049766 0.0055998.888 p < 0.001  
 DM with amputation admissions  
 $\beta_0$ : intercept -8.955374 0.023377-383.09 p < 0.001  
 $\beta_1$ : time point 0.0509460.00458411.12 p < 0.001  
 Note: SE: Standard error, CI: Confidence interval, DM: Diabetes mellitus, CKD: Chronic kidney disease, MI: Myocardial infarction  
 (Results, page 16, line 9 to page 17, line 2 )

Was the age and sex distribution of the population in 2009 ever published? If so, a reference would be needed in the data analysis section.

Thank you so much for your inquiry. We are afraid the age and sex distribution of the UCS population in 2009 has not been published. The data of UCS population of 2009 we used was provided by the National Health Security Office (NHSO), Thailand.

as the standard for age- and sex-adjustment.

"the expected number of admissions in region": please provide more details (ex.: according to the literature, the country level of admission, etc.)

We appreciate your enquiry. "The expected number of admissions in region" is explained as follows in Materials and methods: Data analysis section.

"We estimated the standardized admission ratio (SAR) of each region using the following equation for each region.

$$[SAR]_i = o_i / e_i$$

$$e_i = \sum_{j=1}^J [p_j n_{ij}]$$

where SAR<sub>i</sub> is standardized admission ratio in region i; o<sub>i</sub> is the observed number of admissions in region i; e<sub>i</sub> is the expected number of admissions in region i; j is the population stratum defined by age and sex; p<sub>j</sub> is standard admission rate in the 2009 UCS population for the population stratum j." (Materials and methods: Data analysis, page 10, lines 9-15 )

"Age was categorized into 15 groups of five-year intervals" is not fully accurate, and the last category is 85 to 100 years old. This should be adjusted.

Thank you so much for pointing it out. We have corrected the sentence as shown below and changed the value labels from "85+" to "85-100" in figures and tables.

"Age was categorized into 15 groups in intervals of five years, except the last category that includes 85 to 100 years of age" (Materials and methods: Data analysis, page 10, lines 16-17 )

Minor comments:

Fig 3, "cases with ampulation" should be written "amputation"

Thank you for pointing it out. We corrected the word in the figure.

Fig 4, this would be beautiful without all the diagonals across the pictures. Any way to

remove it?

Thank you very much again. We assume that “the diagonals across the pictures” are the ones shown on the right. These lines appear on some computers, but not all. In fact, we did not see the lines on our computers. We hope the editor has a technical means to solve this problem.

Additional editor comments:

Journal requirements:

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Thank you very much for your kind advice with useful URLs. We have carefully revised our manuscript in accordance with the PLOS ONE style.

In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. Moreover, in you Data statement, please ensure that it is clear how you obtained the data, and how other researchers can request access to the same database.

Thank you very much for bringing out this issue. We obtained the data in the National Health Security Office which manages the database as the first author belongs to the organization. However, we added the sentence clarifying that all data were anonymous, as shown below. We also added the information of how others can access to the database in the “Data reporting” section, as follows.

“All data were fully anonymized before we accessed them.” (Materials and methods: Data, page 8, lines 8-9)

“All patient records were fully anonymized before we accessed. The relevant UCS data are available upon request to the National Health Security Office, Thailand, with the research outline and the details of the required data.” (Data reporting, page 25, lines 15-17)

Our internal editors have looked over your manuscript and determined that it is within the scope of our Health Inequities and Disparities Research Call for Papers. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

Thank you very much for inviting us to the special research call. As indicated in the cover letter, we would like our manuscript to be considered for this collection. We note that you have indicated that data from this study are available upon request. In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

Thank you very much for pointing this out. The National Health Security Office (NHSO) follows the Information Security Policy, Information Security Management System procedure (QP-407 10-001). An individual who wishes to use the UCS databases must

sign the Non-Disclosure Agreement (NDA) with NHSO, and submit copies of documents, reports, articles or publications that use the data. The use of the data is restricted within the research framework and the person should be responsible for his/her own actions in case of a lawsuit, etc. We have added the information to the revised cover letter.

PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.

The corresponding author checked it and he ensured that the ORCID iD was validated in Editorial Manager.

Your ethics statement must appear in the Methods section of your manuscript. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

Thank you very much for your kind reminder. We have added the ethics statement in the Methods section as shown below.

“Ethics of the study was approved by the Institutional Review Board of the National Center for Global Health and Medicine (NCGM) in Japan on 11 May 2018 (NCGM-G-002524-00).” (Materials and methods: Data analyses, page 11, lines 11-12)

We note that Figure 4 in your submission contains map images which may be copyrighted. We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission.

We have created the map images with the geodatabase retrieved from the website, the Humanitarian Development Exchange (HDX). As far as our understanding, all the databases offered under the CC BY license are free to share and or adapt for any purpose, even commercially. It is also stated that no one can apply legal terms or technological measures that legally restrict others from doing anything the license permits (please see the website from <https://data.humdata.org/about/license>).

If there are any problem about license of the map images, please let us know.

Please upload a copy of Supporting Information Table 1 and 2, which you refer to in your text on page 14.

Thank you very much for your concern. We finally decided not to include Supplementary table 1 and 2, but missed deleting the sentence which indicates the Supplementary tables in the manuscript. This time, we deleted the sentence.

**Additional Information:**

| Question  | Response  |
|---|---|
| <p><b>Financial Disclosure</b></p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the <a href="#">submission guidelines</a> for detailed requirements. View published research articles from <a href="#">PLOS ONE</a> for specific examples.</p> <p>This statement is required for submission and <b>will appear in the published article</b> if the submission is accepted. Please make sure it is accurate.</p> | <p>This study was partially funded by Institute for Global Health Policy Research (iGHP), Japan; the Japan International Cooperation Agency (JICA), Japan; and the National Health Security Office, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p> |

**Unfunded studies**

Enter: *The author(s) received no specific funding for this work.*

**Funded studies**

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

\* typeset

**Competing Interests**

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement **will appear in the published article** if the submission is accepted. Please make sure it is accurate. View published research articles from [PLOS ONE](#) for specific examples.

The authors have declared that no competing interests exist.

**NO authors have competing interests**

Enter: *The authors have declared that no competing interests exist.*

**Authors with competing interests**

Enter competing interest details beginning with this statement:

*I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]*

\* typeset

**Ethics Statement**

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

The study was approved by the Institutional Review Board of the National Center for Global Health and Medicine in Japan on May 11, 2018 (NCGM-G-002524-00).



**Format for specific study types**

**Human Subject Research (involving human participants and/or tissue)**

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

**Animal Research (involving vertebrate animals, embryos or tissues)**

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

**Field Research**

Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

**Data Availability**

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

No - some restrictions will apply

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

**Important:** Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

**Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.**

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following: *All relevant data are within the manuscript and its Supporting Information files.*
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

*Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.*

*The data underlying the results presented in the study are available from (include the name of the third party*

Data cannot be shared publicly because the owner of this data, the National Security Office, Thailand, prohibits us to share the data.

*and contact information or URL).*

- This text is appropriate if the data are owned by a third party and authors do not have permission to share the data.

\* typeset

Additional data availability information:

Tanapat Laowahutanon, MSc  
National Health Security Office, Building B 120 Moo 3 Chaengwattana Road, Lak Si  
District, Bangkok 10210, Thailand  
Tel.+66-21-414000; Fax. +66-21-439730-1; E-mail: [tanapat.1@nhso.go.th](mailto:tanapat.1@nhso.go.th)

September 17, 2019

Dear Editors:

We are writing to you to submit our manuscript, “Hospital admission in patients with type 2 diabetes mellitus in Thailand under the Universal Coverage Scheme: a time- and geographical-trend analysis, 2009–2016” for consideration for publication in *PLoS One*.

Thailand has achieved remarkable improvements in population health since the initiation of universal health coverage in 2002. However, it has not been assessed whether the system is reducing the burden of disease effectively in the country. One of the emerging disease burdens in Thailand is diabetes whose prevalence increased from 2.3% in 1991 to 9.6% in 2016. Improper management of diabetes often results in complications including kidney failure, vision loss, and leg amputation. Diabetes increases premature death, reduces quality of life, and increases healthcare cost. The National Health Examination Survey reported that only 23.5% of people with type 2 diabetes mellitus (T2DM) that accounts for more than 94.0% of the total diabetic cases in the country, were treated with fasting plasma glucose levels below 130/dL, and moreover, 43.0% of cases were undiagnosed in 2014.

Our results show that the admission rates of T2DM and its five major complications increased and intra-country geographic inequalities were observed from 2009 to 2016 in Thailand. We warned the country to take this trend seriously and improve health system and policies to enhance primary and secondary prevention of T2DM at this point of population transition, while further studies to be conducted to investigate the reasons behind these trends. We strongly believe that this paper has extremely important implications as regards to accelerated global efforts to reduce burden of diseases, while pursuing universal health coverage.

This manuscript has not been published in part or in whole elsewhere. I attest to the fact that all authors listed on the title page have read and contributed to the manuscript substantially and agreed on its current submission to *PLoS One*. There are no conflicts of interest, corporate involvement or patent holdings for any of the authors.

Thank you for considering this manuscript for publication.

Yours sincerely,  
Tanapat Laowahutanon

1 **Full title:** Hospital admission in patients with type 2 diabetes mellitus in Thailand under the  
2 Universal Coverage Scheme: a time- and geographical-trend analysis, 2009–2016

3  
4 **Short title:** Type 2 diabetes mellitus in Thailand

5  
6 **Authors:** Tanapat Laowahutanon<sup>1#</sup>, Haruyo Nakamura<sup>2,3#</sup>, Hisateru Tachimori<sup>2,4†#</sup>, Shuhei Nomura<sup>2,3</sup>,  
7 Tippawan Liabsuetrakul<sup>5</sup>, Apiradee Lim<sup>6</sup>, Petch Rawdaree<sup>7</sup>, Netnapis Suchonwanich<sup>8</sup>, Hiroyuki  
8 Yamamoto<sup>9</sup>, Kenji Shibuya<sup>10</sup>, Hiroaki Miyata<sup>2,11</sup>, Virasakdi Chongsuvivatwong<sup>5</sup>

9 #Authors contributed equally to this work and share the co-first authorship

10  
11 **Affiliations:**

- 12 1. National Health Security Office, Thailand
- 13 2. Institute for Global Health Policy Research (iGHP), Bureau of International Health  
14 Cooperation National Center for Global Health and Medicine, Japan
- 15 3. Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo,  
16 Japan
- 17 4. Department of Clinical Epidemiology, Translational Medical Center, National Center of  
18 Neurology and Psychiatry, Japan
- 19 5. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla,  
20 Thailand
- 21 6. Department of Mathematics and Computer Science, Faculty of Science and Technology,  
22 Prince of Songkla University Pattani Campus, Thailand
- 23 7. Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj  
24 University, Thailand
- 25 8. The Health Intervention and Technology Assessment Program (HITAP), Thailand
- 26 9. Department of Healthcare Quality Assessment, Graduate School of Medicine, The University  
27 of Tokyo, Japan
- 28 10. Institute for Population Health, King's College London, The United Kingdom
- 29 11. Department of Health Policy and Management, Keio University School of Medicine, Japan

30  
31 † Corresponding author

32 Email: htachimori@it.ncgm.go.jp (HT)

33  
34 # These authors contributed equally to the work.

35  
36 **Word count (abstract):** 300

37 **Word count (main text):** 3,612

38 **Tables:** 2

- 1 **Figures:** 4
- 2 **References:** 36
- 3

## 1 **Abstract**

## 2 **Background**

3 To estimate the time and geographical trends of nationwide admission rates of type 2 diabetes mellitus  
4 (T2DM) and its complications, including chronic kidney disease (CKD), myocardial infarction,  
5 cerebrovascular diseases, retinopathy, cataract, and diabetic foot amputation, descriptive analyses of  
6 2009-2016 were performed using the data of the Universal Coverage Scheme (UCS) which covers  
7 nearly 70 percent of the Thai population.

8

## 9 **Methods and findings**

10 The database of T2DM patients aged 15-100 years who were admitted between 2009 and 2016 under  
11 the UCS and that of the UCS population were retrieved for the analyses. The admitted cases of T2DM  
12 were extracted from the database using disease codes of principal and secondary diagnoses defined by  
13 the International Classification of Diseases 9th and 10th Revisions. The T2DM admission rates in 2009-  
14 2016 were the number of admissions divided by the number of the UCS population. The standardized  
15 admission ratios (SARs) were further estimated in contrast to the expected number of admissions  
16 considering age and sex composition of the UCS population in each region.

17

18 A linearly increased trend was found in T2DM admission rates from 2009 to 2016. Female admission  
19 rates were persistently higher than that of males. In 2016, an increase in the T2DM admission rates was

1 observed among the older ages relative to that in 2009. Although the SARs of T2DM were generally  
2 higher in Bangkok and central regions in 2009, except that with CKD and foot amputation which had  
3 higher trends in northeastern regions, the geographical inequalities were fairly reduced by 2016.

4

## 5 **Conclusion**

6 Admission rates of T2DM and its major complications increased in Thailand from 2009 to 2016.  
7 Although the overall geographical inequalities in the SARs of T2DM were reduced in the country,  
8 further efforts are required to improve the health system and policies focusing on risk factors and  
9 regions to manage the increasing T2DM.



# 1 **Introduction**

2 In the world, approximately 451 million people aged 18 to 99 years lived with diabetes in 2017 [1], and  
3 this number is projected to further increase to 693 million by 2045 [1]. When diabetes is not properly  
4 managed, complications develop typically in kidney failure, vision loss, and foot amputation. Diabetes  
5 has increasingly become a global burden of disease that increases premature death, reduces quality of  
6 life and drives up healthcare cost [2]. The World Health Organization (WHO) emphasizes importance  
7 of prevention and early diagnosis of diabetes, particularly for type 2 diabetes mellitus (T2DM) which  
8 can be effectively reduced through population-based and individual prevention measures that target key  
9 risk factors [3].

10

11 In Thailand, prevalence of diabetes increased from 2.3% in 1991 [4] to 9.6% (6.5 million diabetes cases)  
12 in 2016 [5]. More than 94.0% of diabetic cases in the country are T2DM [2] and the six major diabetic  
13 complications that are annually screened in the country include chronic kidney disease (CKD),  
14 myocardial infarction (MI), cerebrovascular diseases, retinopathy, cataract and foot amputation [6]. The  
15 National Health Examination Survey in 2014 found that only 23.5% of people with T2DM were treated  
16 with fasting plasma glucose being less than 130 mg/dL, while 43.0% of them were undiagnosed [7].

17

18 Thailand has achieved remarkable improvements in population health since the achievement of  
19 universal health coverage (UHC) in 2002. Major health protection schemes in the country include the

1 Civil Service Medical Benefit Scheme, the Social Security Scheme and the Universal Coverage Scheme  
2 (UCS). The last one, taken care by the National Health Security Office (NHSO), covers more than 48  
3 million people, approximately 69.9% of the Thai population as of 2019 [8]. NHSO has 13 Regional  
4 Offices (see Fig 1) sharing all resources and regulation [9]. The UCS is financed by general tax revenue.  
5 The UCS offers the patients with T2DM and its complications the comprehensive benefit package  
6 which includes prevention, curative and rehabilitation services. The beneficiaries are systematically  
7 required to visit the registered primary care facility as the first point of contact. In case of severe  
8 conditions, they are referred to secondary and tertiary care facilities [10]. The UCS applies mixed-  
9 method provider payments, with mainly close-ended capitation for outpatient care and based on  
10 diagnosis-related groups, with a global budget, for inpatient care [11].

11

### 12 **Fig 1. National Health Security Organization regions**

13

14 Despite the national efforts in the implementation of UCS, there is evidence of a rise in intra-national  
15 health inequalities in diabetic mortality rates in Thailand [12]. However, the level of health inequalities  
16 in morbidity measures such as hospital admission has not been well documented. To fill the knowledge  
17 gap, in this paper, we 1) described for the first time a time-trend analysis of nationwide admission rates  
18 of T2DM and its six major diabetic complications among the UCS beneficiaries in Thailand from 2009  
19 to 2016, and 2) assessed regional inequality in trend of the admission ratios across the 13 NHSO

- 1 Regions. We aim to provide the basis for planning and carrying out action in terms of necessary health
- 2 provision and preventive measures.

# 1 **Materials and methods**

## 2 **Data**

3 The data set stored at the NHSO compiled from three data sources were used for this study. Two are  
4 reports sent from hospitals to the Ministry of Public Health, namely the hospital admission database  
5 and the operation database, which include personal national identification number, sex, date of birth,  
6 the NHSO Region, province of hospitalization, hospital code of registration, hospital code of admission,  
7 date of admission, date of discharge, date of death, and principal and secondary diagnoses. The  
8 remaining is compiled from hospital reports sent to the NHSO for reimbursement. All data were fully  
9 anonymized before we accessed them.

10

11 All Thai citizens entitled to use the UCS are registered in a special table of the NHSO datasets. These  
12 are updated annually against birth and death registries taken care by the Ministry of Interior. Although  
13 the NHSO database contains admissions of patients covered by all medical benefit schemes, only those  
14 entitled to the UCS were used for this study. These data are regularly checked to prevent duplication  
15 based on personal national ID number, names and birthdates. After careful data cleaning, a total of  
16 4,297,321 T2DM admitted cases of 2,689,642 UCS patients aged 15 to 100 years in Thailand between  
17 2009 and 2016 were included in this study. Although Thailand achieved UHC in 2002, we decided to  
18 use only data from 2009 onwards for our analyses since there were a number of missing values and  
19 errors in data before 2009 [13, 14]. Ages of below 15 years were excluded because T2DM was rare in

1 children until recently [13] and above 100 years were considered to be primarily caused by typing errors.

2 All subsequent analyses were done on data of the UCS population as denominators and those of the

3 UCS admissions for T2DM as numerators.

4

## 5 **Definitions of T2DM and its complications**

6 A trained medical statistic officer at the hospitals entered diagnosis of T2DM and its complications,

7 CKD, MI, cerebrovascular diseases, retinopathy and cataract based on the International Classification

8 of Diseases 10th Revision (ICD-10) [14], and diabetic foot amputation based on the International

9 Classification of Diseases 9th Revision (ICD-9) [15]. All UCS admitted cases whose principal or

10 secondary diagnosis was coded as T2DM (E11.1 to E11.9), with or without CKD (N18.1 to N18.6,

11 N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21 and I22), cerebrovascular diseases (I60 to I69),

12 retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8, H25.9, H26.0 to H26.4, H26.8, H26.9, and

13 H28.0), or diabetic foot amputations (8410-8417) were included, and any other cases were excluded

14 from this study. Stage 3 or higher stages of CKD are usually considered as diabetic complications.

15 However, stage 1 and 2 of CKD were also included in this study because the ICD-10 code, E11.2

16 includes all stages of kidney complications, and thus it was impossible to exclude stage 1 and 2 of CKD

17 cases. T2DM cases with acute, as well as subsequent MI were included in this study. While only H36.0,

18 diabetic retinopathy was considered as a diabetic complication, all types of cataract were included in

19 this study because diabetic cataract is often misdiagnosed as other types of cataract. Diagnosis of foot

1 amputation was considered as a diabetic complication if it was performed from the toe to above the  
2 knee.

3

#### 4 **Data analysis**

5 Descriptive analyses using the retrospective data were performed to summarize age, sex and regional  
6 structure of the UCS patients who were admitted for T2DM between 2009 and 2016 in Thailand and  
7 the trends in 2009 and 2016 were compared to depict the change in the trends over the eight years.

8

9 We estimated the standardized admission ratio (SAR) of each region using the following equation for  
10 each region.

$$11 \quad SAR_i = \frac{o_i}{e_i}$$
$$12 \quad e_i = \sum_{j=1}^J p_j n_{ij}$$

13 where  $SAR_i$  is standardized admission ratio in region  $i$ ;  $o_i$  is the observed number of admissions in region  
14  $i$ ;  $e_i$  is the expected number of admissions in region  $i$ ;  $j$  is the population stratum defined by age and  
15 sex;  $p_j$  is standard admission rate in the 2009 UCS population for the population stratum  $j$ . Age was  
16 categorized into 15 groups in intervals of five years, except the last category that includes 85 to 100  
17 years of age.

18

1 To estimate temporal trend of admissions, we conducted time series regressions with the following  
2 negative binomial regression model.

$$3 \quad n_i \sim \text{NegativeBinomial}(\mu_i, \phi)$$

$$4 \quad \mu_i = \exp(\beta_0 + \beta_1 x + \log N_i)$$

5 where  $n_i$  is the number of admissions of  $i$ th time point,  $N_i$  is the number of UC population of  $i$ th time  
6 point,  $x$  is the indicator variable of time points,  $\mu$  is the mean parameter and  $\phi$  is dispersion parameter  
7 of Negative Binomial distribution,  $\beta_0$  is the intercept, and  $\beta_1$  is the slope parameter.

8

9 R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria) [16] was used to analyze the  
10 data. To draw choropleth maps, we used R version 3.4.1 with package ‘sf’ [17] and package ‘ggplot2’  
11 [18]. Ethics of the study was approved by the Institutional Review Board of the National Center for  
12 Global Health and Medicine (NCGM) in Japan on 11 May 2018 (NCGM-G-002524-00).

# 1 Results

2 Table 1 presents the number and demographic characteristics of the UCS patients admitted for T2DM  
 3 in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0% of the  
 4 total population of 2009-2016 in Thailand. Over 60% of T2DM patients were female throughout the  
 5 period, although the sex disparity narrowed in the eight years. The mean age (SD) of the UCS T2DM  
 6 patients was 63.1 (12.2) years throughout the years and it annually rose by 0.2 years on average. The  
 7 overall number of UCS patients with T2DM annually increased by 5.4%, and 14.4% among the 85 year-  
 8 olds and older from 2009 to 2016. The number of T2DM patients proportionately increased in Region  
 9 9 (Nakhon Ratchasima), 10 (Ubon Ratchathani) and 11 (Songkhla), and decreased in Region 4  
 10 (Saraburi), 5 (Ratchaburi) and 13 (Bangkok) in the study period.

11

12 **Table 1. Number and demographic characteristics of the Universal Coverage Scheme patients**  
 13 **admitted for type 2 diabetes mellitus in 2009-2016**

|            | 2009                  | 2010                  | 2011                  | 2012                  | 2013                  | 2014                  | 2015                  | 2016                  |
|------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|            | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) | n (%) or<br>mean (SD) |
| <b>Sex</b> |                       |                       |                       |                       |                       |                       |                       |                       |
| Female     | 181,402<br>(66.1)     | 193,297<br>(65.8)     | 202,297<br>(64.9)     | 208,632<br>(64.2)     | 219,830<br>(63.6)     | 228,533<br>(63.1)     | 239,283<br>(62.9)     | 247,671<br>(62.4)     |
| Male       | 92,938<br>(33.9)      | 100,420<br>(34.2)     | 109,310<br>(35.1)     | 116,190<br>(35.8)     | 125,870<br>(36.4)     | 133,426<br>(36.9)     | 141,304<br>(37.1)     | 149,239<br>(37.6)     |
| <b>Age</b> |                       |                       |                       |                       |                       |                       |                       |                       |
| 15-19      | 364<br>(0.1)          | 355<br>(0.1)          | 393<br>(0.1)          | 373<br>(0.1)          | 393<br>(0.1)          | 449<br>(0.1)          | 489<br>(0.1)          | 478<br>(0.1)          |
| 20-24      | 547                   | 608                   | 628                   | 703                   | 755                   | 776                   | 801                   | 876                   |



|                 |                  |                  |                  |                  |                  |                  |                  |                  |
|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                 | (0.2)            | (0.2)            | (0.2)            | (0.2)            | (0.2)            | (0.2)            | (0.2)            | (0.2)            |
| 25-29           | 1,113<br>(0.4)   | 1,104<br>(0.4)   | 1,133<br>(0.4)   | 1,209<br>(0.4)   | 1,253<br>(0.4)   | 1,335<br>(0.4)   | 1,486<br>(0.4)   | 1,551<br>(0.4)   |
| 30-34           | 2,478<br>(0.9)   | 2,582<br>(0.9)   | 2,632<br>(0.8)   | 2,696<br>(0.8)   | 2,888<br>(0.8)   | 2,913<br>(0.8)   | 3,126<br>(0.8)   | 3,156<br>(0.8)   |
| 35-39           | 5,603<br>(2.0)   | 5,938<br>(2.0)   | 5,976<br>(1.9)   | 6,100<br>(1.9)   | 6,233<br>(1.8)   | 6,541<br>(1.8)   | 6,739<br>(1.8)   | 6,822<br>(1.7)   |
| 40-44           | 11,867<br>(4.3)  | 12,206<br>(4.2)  | 12,351<br>(4.0)  | 12,733<br>(3.9)  | 13,053<br>(3.8)  | 13,424<br>(3.7)  | 13,980<br>(3.7)  | 13,787<br>(3.5)  |
| 45-49           | 20,490<br>(7.5)  | 21,236<br>(7.2)  | 21,809<br>(7.0)  | 22,798<br>(7.0)  | 23,893<br>(6.9)  | 24,565<br>(6.8)  | 25,236<br>(6.6)  | 25,353<br>(6.4)  |
| 50-54           | 30,357<br>(11.1) | 31,468<br>(10.7) | 32,063<br>(10.3) | 33,243<br>(10.2) | 35,080<br>(10.1) | 36,049<br>(10.0) | 37,860<br>(9.9)  | 39,043<br>(9.8)  |
| 55-59           | 39,833<br>(14.5) | 42,140<br>(14.3) | 43,507<br>(14.0) | 44,951<br>(13.8) | 46,174<br>(13.4) | 47,384<br>(13.1) | 49,119<br>(12.9) | 50,468<br>(12.7) |
| 60-64           | 42,231<br>(15.4) | 46,458<br>(15.8) | 50,187<br>(16.1) | 53,045<br>(16.3) | 56,747<br>(16.4) | 59,059<br>(16.3) | 61,020<br>(16.0) | 63,304<br>(15.9) |
| 65-69           | 41,038<br>(15.0) | 43,357<br>(14.8) | 45,925<br>(14.7) | 47,328<br>(14.6) | 51,427<br>(14.9) | 55,209<br>(15.3) | 60,056<br>(15.8) | 64,124<br>(16.2) |
| 70-74           | 37,359<br>(13.6) | 40,155<br>(13.7) | 42,922<br>(13.8) | 44,155<br>(13.6) | 46,068<br>(13.3) | 47,329<br>(13.1) | 48,787<br>(12.8) | 50,920<br>(12.8) |
| 75-79           | 24,996<br>(9.1)  | 27,241<br>(9.3)  | 30,523<br>(9.8)  | 32,103<br>(9.9)  | 34,926<br>(10.1) | 37,129<br>(10.3) | 39,243<br>(10.3) | 40,946<br>(10.3) |
| 80-84           | 11,356<br>(4.1)  | 13,362<br>(4.5)  | 15,093<br>(4.8)  | 16,484<br>(5.1)  | 18,459<br>(5.3)  | 20,367<br>(5.6)  | 21,998<br>(5.8)  | 24,058<br>(6.1)  |
| 85+             | 4,708<br>(1.7)   | 5,507<br>(1.9)   | 6,465<br>(2.1)   | 6,901<br>(2.1)   | 8,351<br>(2.4)   | 9,430<br>(2.6)   | 10,647<br>(2.8)  | 12,024<br>(3.0)  |
| Mean (SD)       | 62.4<br>(12.0)   | 62.6<br>(12.1)   | 63.0<br>(12.1)   | 63.1<br>(12.1)   | 63.3<br>(12.2)   | 63.5<br>(12.2)   | 63.7<br>(12.3)   | 63.9<br>(12.3)   |
| NHSO Regions    |                  |                  |                  |                  |                  |                  |                  |                  |
| 1. Chiang Mai   | 19,572<br>(7.1)  | 21,232<br>(7.2)  | 22,492<br>(7.2)  | 23,021<br>(7.1)  | 23,995<br>(6.9)  | 25,160<br>(7.0)  | 26,715<br>(7.0)  | 28,366<br>(7.1)  |
| 2. Phitsanulok  | 14,631<br>(5.3)  | 15,857<br>(5.4)  | 16,760<br>(5.4)  | 18,195<br>(5.6)  | 19,024<br>(5.5)  | 19,455<br>(5.4)  | 20,411<br>(5.4)  | 20,937<br>(5.3)  |
| 3. Nakhon Sawan | 13,592<br>(5.0)  | 15,699<br>(5.3)  | 16,764<br>(5.4)  | 17,646<br>(5.4)  | 17,999<br>(5.2)  | 18,288<br>(5.1)  | 18,974<br>(5.0)  | 19,865<br>(5.0)  |
| 4. Saraburi     | 23,401<br>(8.5)  | 25,965<br>(8.8)  | 26,257<br>(8.4)  | 25,344<br>(7.8)  | 26,249<br>(7.6)  | 27,420<br>(7.6)  | 28,995<br>(7.6)  | 30,772<br>(7.8)  |

|                      |                  |                  |                  |                  |                  |                  |                  |                  |
|----------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| 5. Ratchaburi        | 27,208<br>(9.9)  | 28,203<br>(9.6)  | 30,047<br>(9.6)  | 29,901<br>(9.2)  | 31,538<br>(9.1)  | 32,479<br>(9.0)  | 33,122<br>(8.7)  | 34,033<br>(8.6)  |
| 6. Rayong            | 22,439<br>(8.2)  | 24,207<br>(8.2)  | 26,634<br>(8.5)  | 27,231<br>(8.4)  | 28,588<br>(8.3)  | 29,743<br>(8.2)  | 30,891<br>(8.1)  | 33,143<br>(8.4)  |
| 7. Khon Kaen         | 27,623<br>(10.1) | 30,320<br>(10.3) | 32,205<br>(10.3) | 34,357<br>(10.6) | 36,748<br>(10.6) | 39,207<br>(10.8) | 40,608<br>(10.7) | 41,217<br>(10.4) |
| 8. Udon Thani        | 27,032<br>(9.9)  | 28,833<br>(9.8)  | 30,200<br>(9.7)  | 30,522<br>(9.4)  | 33,339<br>(9.6)  | 35,563<br>(9.8)  | 37,644<br>(9.9)  | 38,258<br>(9.6)  |
| 9. Nakhon Ratchasima | 26,587<br>(9.7)  | 27,945<br>(9.5)  | 30,292<br>(9.7)  | 33,091<br>(10.2) | 36,295<br>(10.5) | 38,139<br>(10.5) | 41,198<br>(10.8) | 44,157<br>(11.1) |
| 10. Ubon Ratchathani | 20,241<br>(7.4)  | 20,368<br>(6.9)  | 22,361<br>(7.2)  | 23,425<br>(7.2)  | 25,384<br>(7.3)  | 26,835<br>(7.4)  | 29,299<br>(7.7)  | 30,886<br>(7.8)  |
| 11. Surat Thani      | 14,498<br>(5.3)  | 15,659<br>(5.3)  | 16,723<br>(5.4)  | 18,423<br>(5.7)  | 19,504<br>(5.6)  | 21,075<br>(5.8)  | 21,777<br>(5.7)  | 22,817<br>(5.7)  |
| 12. Songkhla         | 14,515<br>(5.3)  | 14,903<br>(5.1)  | 15,888<br>(5.1)  | 17,570<br>(5.4)  | 19,069<br>(5.5)  | 19,613<br>(5.4)  | 20,591<br>(5.4)  | 21,288<br>(5.4)  |
| 13. Bangkok          | 23,001<br>(8.4)  | 24,526<br>(8.4)  | 24,984<br>(8.0)  | 26,096<br>(8.0)  | 27,968<br>(8.1)  | 28,982<br>(8.0)  | 30,362<br>(8.0)  | 31,171<br>(7.9)  |
| Total                | 274,340          | 293,717          | 311,607          | 324,822          | 345,700          | 361,959          | 380,587          | 396,910          |

1 Note: The Universal Coverage Scheme (UCS) patients admitted for T2DM are the UCS beneficiaries who  
2 were admitted for type 2 diabetes mellitus (T2DM) between 2009 and 2016. The number of UCS patients  
3 was counted as one in a year. That is, a UCS patient who was admitted for T2DM for multiple times in a  
4 year was counted as one in that year. If the same patient was admitted for T2DM in another year, he/she  
5 was counted as one again in the separate year.

6

7 Fig 2 shows the population pyramids of admitted cases with T2DM among the UCS beneficiaries in  
8 Thailand in 2009 and 2016. The female admission rates were persistently higher than that of males both  
9 in 2009 and 2016. The sex disparity in the admission rates widened between their 30s and 70s. In 2009,  
10 the admission rates of both sexes started increasing in their late 30s, females reached a peak at the ages  
11 of 70 to 74 and males at the ages of 75 to 79, and then both declined. In 2016, both sexes reached a

1 peak at the ages of 75-79. Although the trend was similar in the two years, the admission rates were  
2 persistently much higher and the overall increase occurred in older ages in 2016.

3 **Fig 2. Population pyramids of admitted cases with type 2 diabetes mellitus (T2DM)**  
4 **among the Universal Coverage Scheme patients in Thailand in 2009 and 2016**

5 Note: T2DM admission rates are per 1,000 population.

6 Fig 3 presents the number of patients, the number of admissions and the admission rates of T2DM and  
7 those with the six major complications: CKD, MI, cerebrovascular diseases, retinopathy, cataract and  
8 foot amputation from 2009 to 2016 in Thailand. Overall, there was a linearly increased trend in T2DM  
9 admission rates by 5.2% annually. Among the T2DM admissions, 24.0% was associated with CKD in  
10 2009-2016, and the T2DM admission rates with CKD also had a positive linear trend by 10.0% per year.  
11 Admission rates of T2DM with CKD were 3.5/1000, cerebrovascular diseases 1.1/1000, cataract  
12 0.5/1000, MI 0.4/1000, and retinopathy and foot amputation 0.2/1000 population, respectively. It is  
13 noted that the increasing trends of T2DM admission with CKD and cerebrovascular diseases were  
14 visually observable, while those with MI, retinopathy and foot amputation were rather subtle, and that  
15 with cataract was stable.

16 **Fig 3. The number of patients, the number of admissions and admission rates of type 2 diabetes**  
17 **mellitus with and without the five major complications in Thailand from 2009 to 2016**

18 Legend:   
19  
20  
21

1 Note: The number of admissions refers to how many times the Universal Coverage Scheme (UCS) patients were admitted  
 2 for type-2 diabetes mellitus (T2DM) with or without complications in each year, whereas the number of patients refers to  
 3 how many T2DM patients were admitted in the year. A patient could be admitted for multiple times in a year. The admission  
 4 rate is the number of admissions divided by the number of the UCS population. The scale for all T2DM admission rates is  
 5 different from others as it went up to 17.3/1000 in 2016.

6 Table 2 presents the results of the time series regressions to estimate temporal trend of admissions  
 7 showed that all types of T2DM admissions except that with cataract had a significant and positive  
 8 temporal trend.

9 **Table 2. Time series regressions parameters of temporal trend analysis for admissions**

| Parameters                                  | Estimate  | SE       | z value  | p value   |
|---|-----------|----------|----------|-----------|
| All DM admissions                           |           |          |          |           |
| $\beta_0$ : intercept                       | -4.460529 | 0.006002 | -743.16  | p < 0.001 |
| $\beta_1$ : time point                      | 0.050566  | 0.001187 | 42.61    | p < 0.001 |
| DM with CKD admissions                      |           |          |          |           |
| $\beta_0$ : intercept                       | -6.108389 | 0.009446 | -646.64  | p < 0.001 |
| $\beta_1$ : time point                      | 0.095675  | 0.001861 | 51.41    | p < 0.001 |
| DM with MI admissions                       |           |          |          |           |
| $\beta_0$ : intercept                       | -8.11538  | 0.02155  | -376.58  | p < 0.001 |
| $\beta_1$ : time point                      | 0.07541   | 0.00424  | 17.78    | p < 0.001 |
| DM with cerebrovascular diseases admissions |           |          |          |           |
| $\beta_0$ : intercept                       | -7.251687 | 0.009935 | -729.93  | p < 0.001 |
| $\beta_1$ : time point                      | 0.084358  | 0.001941 | 43.47    | p < 0.001 |
| DM with cataract admissions                 |           |          |          |           |
| $\beta_0$ : intercept                       | -7.604557 | 0.046891 | -162.175 | p < 0.001 |
| $\beta_1$ : time point                      | 0.015244  | 0.009283 | 1.642    | 0.101     |
| DM with retinopathy admissions              |           |          |          |           |
| $\beta_0$ : intercept                       | -8.941096 | 0.028458 | -314.181 | p < 0.001 |
| $\beta_1$ : time point                      | 0.049766  | 0.005599 | 8.888    | p < 0.001 |

| DM with amputation admissions |           |          |         |           |
|-------------------------------|-----------|----------|---------|-----------|
| $\beta_0$ : intercept         | -8.955374 | 0.023377 | -383.09 | p < 0.001 |
| $\beta_1$ : time point        | 0.050946  | 0.004584 | 11.12   | p < 0.001 |

1 Note: SE: Standard error, CI: Confidence interval, DM: Diabetes mellitus, CKD: Chronic kidney  
2 disease, MI: Myocardial infarction

3 Fig 4 presents SARs of T2DM and its complications in the NHSO 13 Regions in 2009 and 2016. The  
4 SARs of T2DM were high in central and northeastern regions: 1.20/1000 in Region 4 (Saraburi),  
5 1.22/1000 in Region 5 (Ratchaburi), 1.31/1000 in Region 7 (Khon Kaen) and 1.22/1000 in Region 8  
6 (Udon Thani) in 2009, but they all declined close to the national average by 2016 except Region 7 that  
7 further increased to 1.44/1000. In the same period, the SARs of T2DM increased from 0.88 to 1.05/1000  
8 in Region 9 (Nakhon Ratchasima), and declined from 1.00 to 0.83/1000 in Region 13 (Bangkok). The  
9 SARs of T2DM with CKD were high in northeastern regions in 2009: 1.79/1000 in Region 7 (Khon  
10 Kaen), 1.58/1000 in Region 8 (Udon Thani) and 1.64/1000 in Region 10 (Ubon Ratchathani), but they  
11 all declined to 1.70/1000, 1.45/1000 and 1.60/1000 by 2016, respectively. On the other hand, the SAR  
12 of T2DM with CKD in Region 9 increased from 0.86 to 1.05/1000 in the same period. The SARs of  
13 T2DM with MI was high in Bangkok and central regions in 2009: 1.60/1000 in Region 4 and 1.69/1000  
14 in Region 13 (Bangkok), but they both declined to 1.43/1000 and 1.27/1000 by 2016, respectively. The  
15 SAR of T2DM with MI in Region 7 increased from 0.88 in 2009 to 1.01 in 2016. The SARs of T2DM  
16 with cerebrovascular diseases were also high in Bangkok and central regions in 2009: 1.46/1000 in  
17 Region 4 (Saraburi), 1.35/1000 in Region 5 (Ratchaburi), 1.34/1000 in Region 6 (Rayong) and  
18 1.90/1000 in Region 13 (Bangkok), but they all declined to 1.25/1000, 1.17/1000, 1.30/1000 and

1 1.21/1000 by 2016, respectively. The SARs of T2DM with cerebrovascular diseases increased in  
2 Region 7 and 9 between 2009 and 2016, from 0.83 to 1.03/1000 and 0.65 to 1.11/1000, respectively.  
3 The SAR of T2DM with retinopathy in Region 13 was 4 times higher than the national average in 2009.  
4 Although it declined to 2.77/1000 by 2016, it was still much higher than other regions. In the same  
5 period, the SARs of T2DM with retinopathy increased in Region 8 and 11 (Surat Thani), from 0.43 to  
6 1.11/1000 and 0.52 to 1.00/1000, respectively. The SARs of T2DM with cataract were high in Bangkok  
7 and central regions in 2009: 2.35/1000 in Region 4, 1.95/1000 in Region 5 and 1.64/1000 in Region 13,  
8 but they all declined to 1.40/1000, 1.33/1000 and 1.25/1000 by 2016, respectively. Whereas, the SARs  
9 of T2DM with cataract increased from 0.76 to 1.13/1000 in Region 11 in the same period. The SARs  
10 of T2DM with foot amputation was high in Bangkok and central and northeastern regions in 2009:  
11 1.21/1000 in Regions 4, 1.35/1000 in Region 7, 1.24/1000 in Region 8 and 1.45/1000 in Region 13. By  
12 2016, the SARs of T2DM with foot amputation in Regions 4 and 13 declined to 0.97/1000 and  
13 1.16/1000, respectively, while those further increased in Region 7 and 8 to 1.61/1000 and 1.43/1000,  
14 respectively.

15 **Fig 4. Comparison of age- and sex- standardized admission ratio of type 2 diabetes mellitus and**  
16 **its complications in the NHSO Regions in 2009 and 2016**

17 Note: The standardized admission ratio (SAR) of type 2 diabetes mellitus (T2DM) and its complications were shown in white  
18 if it is the national average. The color changes into red if SAR is higher than the national average, and gray if it is lower than  
19 the national average. The scale for SARs of T2DM with retinopathy is different from others: it continues up to 5.0 because  
20 SAR of T2DM with retinopathy in Bangkok was substantially higher than other regions in 2009.

21

## 1 **Discussion**

2 A linearly increased trend of T2DM admission rates and that with the six major diabetic complications  
3 were found from 2009 to 2016 in Thailand. Female admission rates were persistently higher than that  
4 of males. In 2016, overall increase in the T2DM admission rates was observed among the older ages  
5 relative to that in 2009. Although geographical inequalities in the T2DM admission ratios were found,  
6 the reduced trend in the inequalities was also observed between 2009 and 2016.

7

8 The observed sex disparities in frequency of the T2DM admissions were consistent with the National  
9 Health Examination Surveys [2] and an assessment on quality of care among patients diagnosed with  
10 T2DM and hypertension, which presented that females in Bangkok were 1.13 times more likely to have  
11 HbA1C level of higher than 9.0% [21]. Biology might play a part in observed sex disparities as women  
12 typically transition from prediabetes to diabetes with a worse cardiovascular risk profile and a higher  
13 BMI than men. However, psychosocial factors, such as health-seeking behavior and provision of health  
14 care, play more important part in the differences, which can be addressed through changes in policy  
15 and health-care delivery [22]. It should be noted that high admission rate does not necessarily mean  
16 high prevalence of the disease, as previous studies showed higher percentage of undiagnosed diabetes  
17 [2] and slightly higher fasting plasma glucose among males in Thailand [23].

18

1 While the number of patients, the number of admissions and admission rates of T2DM steadily  
2 increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates,  
3 which were estimated using the national UCS population of 2009 as the standard population, (12.1 in  
4 2009 and 15.0 in 2016, *results not shown*) were rather gradual as compared with the numbers of crude  
5 admissions rates (12.1 in 2009 and 17.3 in 2016). This result suggests that the increase in the T2DM  
6 admission rates is partly due to the increased and aged population of the country. Although further  
7 studies are required, it could imply that Thailand may face the greater burden of T2DM in the future if  
8 the trend of population growth and aging continues in the country.

9  
10 The T2DM admission rates reached a peak at the ages of 70s and then declined in 2009 and 2016  
11 presumably due to premature death of the T2DM patients. The shifted trend of the peak age toward  
12 elderly among females between 2009 and 2016 can be explained by the fact that the T2DM patients had  
13 aged and their longevity had been extended over the eight years [24]. This trend further implies the  
14 need of increased costs of providing diabetes-related care as older adults with diabetes is clearly more  
15 complicated with multiple coexisting medical conditions, particularly macrovascular complications  
16 such as acute myocardial infarction and cerebrovascular diseases and end-stage renal disease [25]. Age  
17 also affects the potential risks of overtreatment of hyperglycemia in the hospital, which often leads to  
18 longer hospitalization, higher medical costs and increased mortality [26][27].

19



1 Among the six diabetic complications, CKD showed the most significant increase between 2009 and  
2 2016. Although Thailand has launched the “Thailand Healthy Lifestyle Strategy 2011-2020 Plan” [28]  
3 to reduce the prevalence, complications, disability, mortality and cost of non-communicable diseases  
4 including diabetes, national screening and prevention program has not yet been in place [4].  
5 Additionally, renal replacement therapy including renal and peritoneal dialysis and kidney  
6 transplantation requires the UCS patients with a co-payment [29], which may have inhibited some of  
7 them from accessing to proper care. Thailand should take this trend seriously as this type of  
8 complication is associated with a substantial burden in terms of mortality, morbidity and healthcare cost  
9 as it often requires costly and long-term care including dialysis. To prevent progression of CKD stage,  
10 the country should strengthen an effective measure, such as glycated hemoglobin control (HbA1c)  
11  $\leq 7.0\%$  [21], as instructed in the Clinical Practice Recommendation for the Evaluation and  
12 Management of Chronic Kidney Disease in Adults 2015 [30]. This study also found that the number  
13 of admitted cases with CKD were 1.7 times greater than the number of patients. This indicates that  
14 many of the patients with diabetic complication of CDK were readmitted, and implies that there might  
15 be unmet needs of inpatient care for the T2DM patients with CKD. Further study should be conducted  
16 to investigate the reasons behind the frequent readmissions and take measures to meet the needs of the  
17 patients.  
18

1 While the SARs of T2DM were higher in Bangkok and central regions relative to other regions in 2009,  
2 except those with CKD and partly foot amputation, they declined in most of the regions by 2016.  
3 Additionally, there was an overall trend of SAR reduction in Bangkok and central regions, where human  
4 and financial resources were traditionally concentrated, and increase in northeastern regions, where the  
5 resources were traditionally scarce, over the eight years [9, 31]. This trend indicates Thailand's  
6 successful health reform by reducing geographical inequalities in inpatient care, which might be a result  
7 of equitably redistributed health professionals, health infrastructure development and rural retention  
8 policies over the past four decades [32].

9

10 On the other hand, the persistently high SAR of T2DM with retinopathy in Bangkok is presumably due  
11 to high density of specialists as half of 1,500 ophthalmologists, including 200 retinal specialists, practice  
12 in Bangkok [33].

13

14 The persistently high SAR of T2DM with CKD in northeastern regions was consistent with a previous  
15 study and partly attributed to high prevalence of CKD in northeastern regions (10.8%) relative to other  
16 regions (north 8.9%, south 8.1% and Bangkok 6.2%) [34], but partly to an association with lower  
17 density of physicians and rurality of the region [13]. The density of physicians in northeastern regions  
18 is the lowest in the country [32], as low as seven times lower than Bangkok [9]. It is reasonable to  
19 assume that in a region where physicians are scarce, T2DM patients with CKD are unlikely to receive

1 timely, thorough and effective treatment, and consequently deteriorate in conditions. This assumption  
2 might explain the high readmission rates of T2DM with CDK, and the highest mortality rates due to  
3 diabetes in northeastern regions as found in another study [12]. Moreover, rurality of the northeastern  
4 regions, where 71.0% of the population reside in rural setting (north 65.6%, south 66.5% and Central  
5 54.5%) [35], might have halted them from accessing adequate primary care. A previous study found a  
6 strong association between the high SAR of diabetes and rurality as the rural population tends to have  
7 lack of public transport alternatives and poor health literacy with less education which often limit  
8 accessibility to health care. The study also suggested that the percentage of patients who had received  
9 up to secondary education was lower in rural districts by approximately 10% [13].

10

11 Inaccessibility to the outpatient data and absence of information indicating direct causality between  
12 diabetes and complicated conditions were the major limitations of this study. For the first limitation, it  
13 is important to monitor the long-term trends of diabetic morbidity starting at onset of disease,  
14 accessibility and quality of outpatient and inpatient care, and health outcome including mortality to  
15 assess the quality of T2DM healthcare in the country. Besides, community involvement in diabetic care  
16 should be also carefully monitored, as approximately 77.0% of cost is involved in non-medical activities  
17 [36], and community-based screening, study and health promotion would be increasingly important for  
18 diabetic care [4]. In this study, we looked at the trend of the inpatient care and tried to capture that of a  
19 series of healthcare, but future study should carefully assess the situations of accessibility and quality

1 of T2DM outpatient care, and coordination of outpatient and inpatient care for the most cost-effective  
2 T2DM healthcare policies in Thailand.

3

4 For the second limitation, we regarded the complications as if they were directly caused by T2DM,  
5 when we found T2DM as either principle or secondary diagnosis and one or more of the major  
6 complications in an individual record of the hospital admission database since it was the only available  
7 information.

8

9 Thailand has achieved great improvement in health care reform invested on equitable health finance  
10 and increased total budget for health expenditures in T2DM and its complications. It is time for the  
11 country to carefully identify the risk factors and regions in particular needs of care for T2DM and its  
12 complications, and plan on the effective and efficient health care which would not leave no one behind  
13 in the country.

## 1 **Acknowledgements**

2 Our special thanks go to the Bureau of Information technology and Bureau of Health information and  
3 Outcome Evaluation, NHSO. They supported and provided us with the hospital data for this research.

4

## 5 **Contributors**

6 TL acquired the data, conceived of and designed the study, and drafted the final manuscript. HT and

7 HN analysed the data, interpret and discuss the results, and drafted the final manuscript. SN, AL and

8 NS designed the statistical framework and supported data analysis. AL and NS confirmed the quality

9 of data and the study design. VC, TL, KS and HM took responsibility for the integrity of the data and

10 the accuracy of the data analysis and will oversee the study. All the authors made critical revisions to

11 the manuscript for important intellectual content, gave final approval of the manuscript, and will support

12 the interpretation and discussion of findings.

13

## 14 **Data reporting**

15 All patient records were fully anonymized before we accessed. The UCS data are available upon request

16 to the National Health Security Office, Thailand, with the research outline and the details of the required

17 data.

## 1 **References**

- 2 1. Cho NH, Show JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF  
3 Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.  
4 Diabetes Res Clin Pract. 2018; 138: 271-281.
- 5 2. Reutrakul S, Deerochanawong C. Diabetes in Thailand: Status and Policy. Curr Diab Rep. 2016  
6 Mar;16(3):28.
- 7 3. World Health Organization. Global Report on Diabetes. Geneva: WHO Press; 2016.
- 8 4. Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature review of the  
9 burden, costs, and outcomes. Global Health. 2013 Mar 14;9:11. doi: 10.1186/1744-8603-9-11.
- 10 5. World Health Organization. Thailand. Diabetes country profiles 2016. Available from:  
11 [https://www.who.int/diabetes/country-profiles/tha\\_en.pdf?ua=1](https://www.who.int/diabetes/country-profiles/tha_en.pdf?ua=1)
- 12 6. Rawdaree P, Deerochanawong C, Chetthakul T, Benjasuratwong Y, Kosachunhanun N,  
13 Leelawatana R, et al. Thailand Diabetes Registry (TDR) project: Clinical status and long term  
14 vascular complications in diabetic patients. J Med Assoc Thai. 2006; 89 (Suppl 1): S1-9.
- 15 7. Aekplakorn W, Puckcharern H, Thaikla K, Satheannoppakao W. The National Health  
16 Examination Survey V. Bangkok: Health Systems Research Institute; 2016.
- 17 8. Worldometers. 2019. Available from: <https://www.worldometers.info/world->  
18 [population/thailand-population/](https://www.worldometers.info/world-population/thailand-population/).


- 1 9. Primary health care systems (PRIMASYS): case study from Thailand, abridged version. Geneva:  
2 World Health Organization; 2017.
- 3 10. National Health Security Office. NHSO UC Information. Bangkok: Executive Information  
4 System; 2019.
- 5 11. Tangatharoensathien V, Limwattaranon S, Patcharanarumol W, Thammatacharee J. Monitoring  
6 and evaluating progress towards universal health coverage in Thailand. PLoS Med.  
7 2014;11(9):e1001726. doi:10.1371/journal.pmed.1001726.
- 8 12. Aungkulanon S, Tangcharoensathien V, Shibuya K, Bundhamcharoen K, Chongsuvivatwong V.  
9 Post universal health coverage trend and geographical inequities of mortality in Thailand. Int J  
10 Equity Health. 2016;15(190). doi: 10.1186/s 12939-016-0479-5.
- 11 13. Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the  
12 district level and health outcomes: a case study of diabetes mellitus care in Thailand. Risk Manag  
13 Healthc Policy. 2018. 11, 199-208
- 14 14. Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates  
15 and Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage  
16 Scheme Data. AJP Rep. 2019; 9(4): 328-336.
- 17 15. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et al.  
18 Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients. J Med  
19 Assoc Thai. 2006;89 Suppl 1:S60-5. Epub 2007/08/25. PubMed PMID: 17715835.



- 1 16. Ministry of Public Health. International Classification of Diseases 10th Revision (ICD10). 2016.  
2 Available from: <http://www.thcc.or.th/ebook1/2016/mobile/index.html#p=1>.
- 3 17. Thai CaseMix Center. ICD-9-CM 2015 Classification of Procedure. 2015. Available from:  
4 <http://www.tcmc.or.th/main/index.php/153-icd9cm2015>.
- 5 18. R Core Team. R: A language and environment for statistical computing. R Foundation for  
6 Statistical Computing, Vienna, Austria. 2019. Available from: <https://www.R-project.org/>.
- 7 19. Pebesma E, Bivand R, Racine E, Sumner M, et al. Simple Features for R. July 3, 2019. [cited  
8 2019 July 3]. Available from: <https://cran.r-project.org/web/packages/sf/sf.pdf>.
- 9 20. Wickham H, Chang W, Henry L, Pedersen TL, et al. Create Elegant Data Visualisations Using the  
10 Grammar of Graphics. Package 'ggplot2.' June 14, 2019. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/ggplot2/ggplot2.pdf)  
11 [project.org/web/packages/ggplot2/ggplot2.pdf](https://cran.r-project.org/web/packages/ggplot2/ggplot2.pdf).
- 12 21. Sonthon P, Promthet S, Changsirikulchai S, Rangsin R, Thinkhamrop B, Rattanamongkolgul S, et  
13 al. The impact of the quality of care and other factors on progression of chronic kidney disease in  
14 Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study. PLoS One. 2017 Jul  
15 28;12(7):e0180977. doi: 10.1371/journal.pone.0180977.
- 16 22. Sex disparities in diabetes: bridging the gap. Lancet Diabetes Endocrinol: Editorial. 2017;  
17 5(11):839




- 1 23. Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuivatwong V, Cheepudomwit S,  
2 et al. The Prevalence and Management of Diabetes in Thai Adults. *Diabetes Care*. 2003; 26(10):  
3 2758-2763. DOI: 10.2337/diacare.26.10.2758.
- 4 24. United Nations, Department of Economic and Social Affairs, Population Division. *World  
5 Population Ageing 2017 - Highlights*. New York: United Nations; 2017
- 6 25. Gregg EW, Li Y, Wang J, Burrows NR, Ali MA, Rolka D, et al. Changes in diabetes-related  
7 complications in the United States, 1990-2010. *N Engl J Med*. 2014;370:1514–1523.
- 8 26. Umpierrez GE, Pasquel FJ. Management of inpatient hyperglycemia and diabetes in older adults.  
9 *Diabetes Care*. 2017;40:509–517.
- 10 27. Alagiakrishnan K, Mereu L. Approach to managing hypoglycemia in elderly patients with  
11 diabetes. *Postgrad Med* 2010;122:129–137
- 12 28. Ministry of Public Health. Thailand healthy lifestyle strategic plan 2011-2020. Available from:  
13 <https://dokumen.tips/documents/thailand-healthy-lifestyle-strategic-plan-2011-2020.html>.
- 14 29. Treerutkuarkul A. Thailand: health care for all, at a price. *Bull World Health Organ*.  
15 2010;88(2):84–85.
- 16 30. Chittinan A, Eiam-ong S, Kantachuvesiri S, Chailimpamontri W. *Clinical Practice  
17 Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults  
18 2015*. 1<sup>st</sup> ed. Bangkok: The Nephrology Society of Thailand; 2015. Available from:


- 1 <http://www.nephrothai.org/images/10-11->  
2 2016/Final\_%E0%B8%84%E0%B8%A1%E0%B8%AD\_CKD\_2015.pdf
- 3 31. Lindelow M, Hawkins L, Osornprasop S. Government spending and central-local relations in  
4 Thailand's health sector. Washington DC: The International Bank for Reconstruction and  
5 Developemnt/The World Bank; 2012.
- 6 32. Witthayapipopsakul W, Cetthakrikul N, Suphanchaimat R, Noree T, Sawaengdee K. Equity of  
7 health workforce distribution in Thailand: an implication of concentration index. Risk Manag  
8 Healthc Policy. 2019;12:13-22.
- 9 33. Ruamviboonsuk P, Krause J, Chotcomwongse P, Sayres R, Raman R, Widner K, et al. Deep  
10 learning versus human graders for classifying diabetic retinopathy severity in a nationwide  
11 screening program. npj Digit Med. 2019; 2(25).
- 12 34. Ong-ajyooth L, Vareesangthip K, Khonputsra P, Aekplakorn W. Prevalence of chronic kidney  
13 disease in Thai adults: a national health survey. BMC Nephrology. 2009; 10(35).
- 14 35. National Statistical Office, Kingdom of Thailand. The 2010 Population and Housing Census.  
15 Bangkok: National Statistical Office; 2012.
- 16 36. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupaijit K, Panpuwong N, et al.  
17 Cost of diabetes and its complications in Thailand: a complete picture of economic burden. Health  
18 Soc Care Community. 2011; 19(3), 289–298.









All DM




DM with CKD




DM with MI




DM with Cerebrovascular diseases




DM with cataract



DM with retinopathy



DM with foot amputation



1 **Full title:** Hospital admission in patients with type 2 diabetes mellitus in Thailand under the  
2 Universal Coverage Scheme: a time- and geographical-trend analysis, 2009–2016

3  
4 **Short title:** Type 2 diabetes mellitus in Thailand

5  
6 **Authors:** Tanapat Laowahutanon<sup>1#</sup>, Haruyo Nakamura<sup>2,3#</sup>, Hisateru Tachimori<sup>2,4†#</sup>, Shuhei Nomura<sup>2,3</sup>,  
7 Tippawan Liabsuetrakul<sup>5</sup>, Apiradee Lim<sup>6</sup>, Petch Rawdaree<sup>7</sup>, Netnapi Suchonwanich<sup>8</sup>, Hiroyuki  
8 Yamamoto<sup>9</sup>, Kenji Shibuya<sup>10</sup>, Hiroaki Miyata<sup>2,11</sup>, Virasakdi Chongsuvivatwong<sup>5</sup>

9 #Authors contributed equally to this work and share the co-first authorship

10  
11 **Affiliations:**

- 12 1. National Health Security Office, Thailand
- 13 2. Institute for Global Health Policy Research (iGHP), Bureau of International Health  
14 Cooperation National Center for Global Health and Medicine, Japan
- 15 3. Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo,  
16 Japan
- 17 4. Department of Clinical Epidemiology, Translational Medical Center, National Center of  
18 Neurology and Psychiatry, Japan
- 19 5. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla,  
20 Thailand
- 21 6. Department of Mathematics and Computer Science, Faculty of Science and Technology,  
22 Prince of Songkla University Pattani Campus, Thailand
- 23 7. Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj  
24 University, Thailand
- 25 8. The Health Intervention and Technology Assessment Program (HITAP), Thailand
- 26 9. Department of Healthcare Quality Assessment, Graduate School of Medicine, The University  
27 of Tokyo, Japan
- 28 10. Institute for Population Health, King's College London, The United Kingdom
- 29 11. Department of Health Policy and Management, Keio University School of Medicine, Japan

30  
31 † Corresponding author

32 Email: htachimori@it.ncgm.go.jp (HT)

33  
34 # These authors contributed equally to the work.

35  
36 **Word count (abstract):** ~~300~~<sup>35</sup>

37 **Word count (main text):** ~~32,612~~<sup>349</sup>

38 **Tables:** ~~2~~<sup>1</sup>

1 **Figures:** 4

2 **References:** ~~3625~~

3



1 **Abstract**

2 **Background**

3 To estimate the time and geographical trends of nationwide admission rates of type 2 diabetes mellitus  
4 (T2DM) and its complications, including chronic kidney disease (CKD), myocardial infarction-~~(MI)~~,  
5 ~~stroke~~cerebrovascular diseases, ~~retinopathy~~, cataract, and diabetic ~~foot~~ amputation, ~~descriptive analyses~~  
6 ~~of 2009-2016 were performed using the data of among~~ the Universal Coverage Scheme (UCS) ~~which~~  
7 ~~covers nearly 70 percent of the Thai population~~beneficiaries across administrative regions of National  
8 ~~Health Security Office (NHSO) in Thailand from 2009 to 2016.~~

9

10 **Methods and findings**

11 The database of T2DM patients aged 15-100 years who were admitted between 2009 and 2016 under  
12 the UCS ~~in Thailand~~ and that of the UCS population were retrieved for the analysis. The admitted  
13 cases of T2DM were extracted from the database using disease codes ~~ing~~ of principal and secondary  
14 diagnoses ~~defined by~~ of the International Classification of Diseases 9th and 10th Revisions ~~(ICD9 and~~  
15 ~~ICD10)~~. The T2DM admission rates in 2009-2016 ~~were the number of admissions divided by the~~  
16 ~~number of the UCS population, were standardized by age and sex to the 2009 UCS population.~~ The  
17 standardized admission ratios (SARs) ~~of each region~~ were further estimated in contrast to the expected  
18 number of admissions considering age and sex composition of the UCS ~~national~~ population ~~in each~~  
19 ~~region~~.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

A linearly increased trend was found in T2DM admission rates from 2009 to 2016. Female admission rates were persistently higher than that of males. In 2016, an increase in the T2DM admission rates was observed among the older ages relative to that in 2009. Although the SARs of T2DM were generally higher in Bangkok and central regions in 2009, except that with CKD and foot amputation which had higher trends in northeastern regions, the geographical inequalities were fairly reduced by 2016.

~~A linearly increased trend of T2DM admission rates at national level from 2009 to 2016 with 3.1% increase per year was found. For the five major diabetic complications, the average annual increase in admission rates from 2009 to 2016 for CKD, myocardial infarction, stroke, cataract and amputation were 10.8%, 5.6%, 7.7%, 0.2%, and 6.1%, respectively. Female admission rates were 1.0 to 2.4 times higher than that of males persistently. In 2009 and 2016, the T2DM admission rates in both sexes started increasing at their late 30s, reached a peak at 60 to 64 and then declined. However, the overall increased rate was observed among the older ages in 2016. The SAR with major diabetic complications were particularly high in Region 3 (Nakhonsawan) (1.5/1,000) and Region 2 (Phitsanulok) (1.5/1,000) in 2009 and that in Region 3 (Nakhonsawan) further increased to 1.8/1,000 in 2016.~~

**Conclusion**

1 Admission rates of T2DM and its major complications ~~have been increased~~ ing in Thailand from 2009  
2 to 2016. Although and the overall intra-country geographical difference inequalities in the SARs of  
3 T2DM were reduced in the country. has been observed in Thailand. further efforts are required to  
4 improve the health system and policies focusing on risk factors and regions to manage the increasing  
5 T2DM. Improving health system and policy to improve the both primary and secondary prevention of  
6 T2DM are required in the country.

## 1 **Introduction**

2 [In the world](#)~~Globally~~, approximately 451 million people aged 18 to 99 years lived with diabetes in 2017  
3 [1], and this number is projected to further increase to 693 million by 2045 [1]. When diabetes is not  
4 properly managed, complications develop typically in kidney failure, vision loss, and ~~leg-foot~~  
5 amputation. Diabetes has increasingly become a global burden of disease that increases premature death,  
6 reduces quality of life and drives up healthcare cost [2]. The World Health Organization (WHO)  
7 emphasizes importance of prevention and early diagnosis of diabetes, particularly for type 2 diabetes  
8 mellitus (T2DM) which can be effectively reduced through population-based and individual prevention  
9 measures that target key risk factors [3].

10

11 In Thailand, prevalence of diabetes increased from 2.3% in 1991 [4] to 9.6% (6.5 million diabetes cases)  
12 in 2016 [5]. More than 94.0% of diabetic cases in the country are T2DM [2] and the ~~five~~~~six~~ major  
13 diabetic complications that are annually screened in the country include chronic kidney disease (CKD),  
14 myocardial infarction (MI), ~~stroke~~~~cerebrovascular diseases~~, ~~retinopathy~~, cataract and ~~amputation~~~~foot~~  
15 ~~amputation~~ [6]. The National Health Examination Survey in 2014 found that only 23.5% of people with  
16 T2DM were treated with fasting plasma glucose being less than 130 ~~mg/dL~~, while 43.0% of them were  
17 undiagnosed [7].

18

1 Thailand has achieved remarkable improvements in population health since the achievement of  
2 universal health coverage (UHC) in 2002. Major health protection schemes in the country include the  
3 Civil Service Medical Benefit Scheme, the Social Security Scheme and the Universal Coverage Scheme  
4 (UCS). The last one, taken care by the National Health Security Office (NHSO), covers more than 48  
5 million people, approximately 69.9% of the Thai population [as of 2019](#) [8]. NHSO has 13 Regional  
6 Offices (see Fig 1) sharing all resources and regulation [9]. The UCS is financed by general tax revenue.  
7 The UCS offers the patients with T2DM and its complications the comprehensive benefit package  
8 which includes prevention, curative and rehabilitation services. The beneficiaries are systematically  
9 required to visit the registered primary care facility as the first point of contact. In case of severe  
10 conditions, they are referred to secondary and tertiary care facilities [10]. The UCS applies mixed-  
11 method provider payments, with mainly close-ended capitation for outpatient care and based on  
12 diagnosis-related groups, with a global budget, for inpatient care [11].

13

14 **Fig 1. National Health Security Organization regions**

15

16 Despite the national efforts in the implementation of UCS, there is evidence of a rise in intra-national  
17 health ~~differences and~~ inequalities in diabetic mortality rates in Thailand [12]. However, the level of  
18 health inequalities in morbidity measures such as hospital admission has not been well documented. To  
19 fill the knowledge gap, in this paper, we 1) described for the first time a time-trend analysis of

1 nationwide admission rates of T2DM and its ~~five~~ six major diabetic complications among the UCS  
2 beneficiaries in Thailand from 2009 to 2016, and 2) assessed ~~difference~~ regional inequality in trend of  
3 the admission ratios across the 13 NHSO Regions. We aim to provide the basis for planning and  
4 carrying out action in terms of necessary health provision and preventive measures.

# 1 **Materials and methods**

## 2 **Data**

3 The data set stored at the NHSO compiled from three data sources were used for this study. Two are  
4 reports sent from hospitals to the Ministry of Public Health, namely the hospital admission database  
5 and the operation database, which include personal national identification number, sex, date of birth,  
6 the NHSO Region, province of ~~hospitalization~~~~residence~~, hospital code of registration, hospital code of  
7 admission, date of admission, date of discharge, date of death, and principal and secondary diagnoses.

8 The remaining is compiled from hospital reports sent to the NHSO for reimbursement. All data were  
9 fully anonymized before we accessed them.

10

11 All Thai citizens entitled to use the UCS are registered in a special table of the NHSO datasets. These  
12 are updated annually against birth and death registries taken care by the Ministry of Interior. Although  
13 the NHSO database contains admissions of patients ~~covered by~~ ~~of~~ all medical benefit schemes, only  
14 those entitled to the UCS were used for this study. These data are regularly checked to prevent  
15 duplication based on personal national ID number, names and birthdates. After careful data cleaning, a  
16 total of 4,297,321 T2DM admitted cases of 2,689,642 UCS patients aged 15 to 100 years in Thailand  
17 between 2009 and 2016 were included in this study. Although Thailand achieved UHC in 2002, we  
18 decided to use only data from 2009 onwards for our analyses since there were a number of ~~many~~ missing  
19 values and errors in data before 2009 [13, 14]. Ages of below 15 years were excluded because T2DM

1 was rare in children until recently [13] and above 100 years were considered to be primarily caused by  
2 typing errors. All subsequent analyses were done on data of the UCS population these as denominators  
3 and those of the UCS admissions for T2DM as numerators.

4

## 5 **Definitions of T2DM and its complications**

6 A trained medical statistic officer at the hospitals entered ~~D~~ diagnosis of T2DM and its complications,  
7 CKD, MI, strokecerebrovascular diseases, retinopathy and cataract ~~were entered at the hospital by a~~  
8 ~~trained medical statistic officer~~ based on the International Classification of Diseases 10th Revision  
9 (ICD-10) [14], and diabetic amputationfoot amputation ~~was defined~~ based on the International  
10 Classification of Diseases 9th Revision (ICD-9) [15]. All UCS admitted cases admitted cases whose  
11 principal ~~or~~ secondary diagnoses ~~is~~ ~~was~~ ~~ere~~ coded as T2DM (E11.1 to E11.9), with or without CKD  
12 (N18.1~~2~~ to N18.6, ~~5~~ or N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21.0 to I21.4 or I21.9 and  
13 I22), strokecerebrovascular diseases (I6.0 to I6.9), retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8,  
14 H25.9, H26.0 to H26.4, H26.8, H26.9, and H28.0), or diabetic amputationfoot amputations (841~~001-~~  
15 ~~84157~~) were included, and any other cases were excluded from this study. Stage 3 or higher stages of  
16 CKD are usually considered as diabetic complications. However, stage 1 and 2 of CKD were also  
17 included in this study because the ICD-10 code, E11.2 includes all stages of kidney complications, and  
18 thus it was impossible to exclude stage 1 and 2 of CKD cases. T2DM cases with acute, as well as  
19 subsequent MI were included in this study. While only H36.0, diabetic retinopathy was considered as



1 a diabetic complication, all types of cataract were included in this study because diabetic cataract is  
2 often misdiagnosed as other types of cataract. Diagnosis of foot amputation was considered as a diabetic  
3 complication if it was performed from the toe to above the knee.

## 5 **Data analysis**

6 Descriptive ~~analyses~~statistics using the retrospective data were ~~us~~performed to summarize age, sex and  
7 regional structure of the UCS patients who were admitted for T2DM between 2009 and 2016 in  
8 Thailand and the trends in 2009 and 2016 were compared to depict the change in the trends over the  
9 eight years.

11 ~~Age and sex standardized T2DM admission rates were estimated using the national UCS population~~  
12 ~~of 2009 as the standard population. Age was categorized into 15 groups in intervals of five years, except~~  
13 ~~the last category that includes 85 to 100 years of age.~~ We estimated the standardized admission ratio  
14 (SAR) of each region using the following equation for each region.

$$SAR_i = \frac{o_i}{e_i}$$
$$e_i = \sum_{j=1}^J p_j n_{ij}$$

17 where  $SAR_i$  is standardized admission ratio in region  $i$ ;  $o_i$  is the observed number of admissions in region  
18  $i$ ;  $e_i$  is the expected number of admissions in region  $i$ ;  $j$  is the population stratum defined by age and  
19 sex;  $p_j$  is standard admission rate in the 2009 UCS population for the population stratum  $j$ . Age was

1 categorized into 15 groups in intervals of five years, except the last category that includes 85 to 100  
2 years of age.

3

4

5 To estimate temporal trend of admissions, we conducted time series regressions with the following  
6 negative binomial regression model.

7 
$$n_i \sim \text{NegativeBinomial}(\mu_i, \phi$$

8 
$$\mu_i = \exp(\beta_0 + \beta_1 x + \log N_i)$$

9 where  $n_i$  is the number of admissions of  $i$ th time point,  $N_i$  is the number of UC population of  $i$ th time  
10 point,  $x$  is the indicator variable of time points,  $\mu$  is the mean parameter and  $\phi$  is dispersion parameter  
11 of Negative Binomial distribution,  $\beta_0$  is the intercept, and  $\beta_1$  is the slope parameter.

12

13 R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria) [16] was used to analyze the  
14 data. To draw choropleth maps, we used R version 3.4.1 with package ‘sf’ [17] and package ‘ggplot2’  
15 [18]. ~~Ethics~~ ~~The~~ ~~of~~ ~~the~~ study was approved by the Institutional Review Board of the National Center  
16 for Global Health and Medicine (NCGM) in Japan on 11 May 2018 (NCGM-G-002524-00).

1 **Results**

2 Table 1 presents the number and demographic characteristics of the UCS patientpopulation admitted  
 3 for T2DM in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0%  
 4 of the total population of 2009-2016 in Thailand. Over 60% of T2DM patients were female throughout  
 5 the period, although the sex disparity narrowed in the eight years. The mean age (SD) of the UCS T2DM  
 6 patientpopulation was 4363.1 (=12.2) years throughout the years and it annually rose by 0.62 years on  
 7 average. The population of over 50 years annually increased by 3.1% on average among the UCS  
 8 population. The overall number of UCS patients with T2DM annually increased by 5.4%, and 14.4%  
 9 among the 85 year-olds and older from 2009 to 2016, population in Region 4 (Saraburi), 6 (Rayong)  
 10 and 13 (Bangkok) annually increased by 1.5%, 1.3% and 0.9%, respectively, while that of Region 1  
 11 (Chiangmai), 3(Nakhonsawan) and 7 (Khonkaen) annually decreased by 3.2%, 0.4% and 0.4%,  
 12 respectively from 2009 to 2016. The number of T2DM patients proportionately increased in Region 9  
 13 (Nakhon Ratchasima), 10 (Ubon Ratchathani) and 11 (Songkhla), and decreased in Region 4 (Saraburi),  
 14 5 (Ratchaburi) and 13 (Bangkok) in the study period.

15

16 **Table 1. Number and dDemographic characteristics of the Universal Coverage Scheme patients**  
 17 **admitted for with type 2 diabetes mellitus in 2009-2016**

|     | 2009                                | 2010                                | 2011                                | 2012                                | 2013                                | 2014                                | 2015                                | 2016                                |
|-----|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|     | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> | <u>n (%) or</u><br><u>mean (SD)</u> |
| Sex |                                     |                                     |                                     |                                     |                                     |                                     |                                     |                                     |

|              |                        |                        |                        |                        |                        |                        |                        |                        |
|--------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Female       | 181,402<br>(66.1)      | 193,297<br>(65.8)      | 202,297<br>(64.9)      | 208,632<br>(64.2)      | 219,830<br>(63.6)      | 228,533<br>(63.1)      | 239,283<br>(62.9)      | 247,671<br>(62.4)      |
| Male         | 92,938<br>(33.9)       | 100,420<br>(34.2)      | 109,310<br>(35.1)      | 116,190<br>(35.8)      | 125,870<br>(36.4)      | 133,426<br>(36.9)      | 141,304<br>(37.1)      | 149,239<br>(37.6)      |
| Age Mean age | <u>62.4</u><br>(±12.0) | <u>62.6</u><br>(±12.1) | <u>63.0</u><br>(±12.1) | <u>63.1</u><br>(±12.1) | <u>63.3</u><br>(±12.2) | <u>63.5</u><br>(±12.2) | <u>63.7</u><br>(±12.3) | <u>63.9</u><br>(±12.3) |
| 15-19        | 364<br>(0.1)           | 355<br>(0.1)           | 393<br>(0.1)           | 373<br>(0.1)           | 393<br>(0.1)           | 449<br>(0.1)           | 489<br>(0.1)           | 478<br>(0.1)           |
| 20-24        | 547<br>(0.2)           | 608<br>(0.2)           | 628<br>(0.2)           | 703<br>(0.2)           | 755<br>(0.2)           | 776<br>(0.2)           | 801<br>(0.2)           | 876<br>(0.2)           |
| 25-29        | 1,113<br>(0.4)         | 1,104<br>(0.4)         | 1,133<br>(0.4)         | 1,209<br>(0.4)         | 1,253<br>(0.4)         | 1,335<br>(0.4)         | 1,486<br>(0.4)         | 1,551<br>(0.4)         |
| 30-34        | 2,478<br>(0.9)         | 2,582<br>(0.9)         | 2,632<br>(0.8)         | 2,696<br>(0.8)         | 2,888<br>(0.8)         | 2,913<br>(0.8)         | 3,126<br>(0.8)         | 3,156<br>(0.8)         |
| 35-39        | 5,603<br>(2.0)         | 5,938<br>(2.0)         | 5,976<br>(1.9)         | 6,100<br>(1.9)         | 6,233<br>(1.8)         | 6,541<br>(1.8)         | 6,739<br>(1.8)         | 6,822<br>(1.7)         |
| 40-44        | 11,867<br>(4.3)        | 12,206<br>(4.2)        | 12,351<br>(4.0)        | 12,733<br>(3.9)        | 13,053<br>(3.8)        | 13,424<br>(3.7)        | 13,980<br>(3.7)        | 13,787<br>(3.5)        |
| 45-49        | 20,490<br>(7.5)        | 21,236<br>(7.2)        | 21,809<br>(7.0)        | 22,798<br>(7.0)        | 23,893<br>(6.9)        | 24,565<br>(6.8)        | 25,236<br>(6.6)        | 25,353<br>(6.4)        |
| 50-54        | 30,357<br>(11.1)       | 31,468<br>(10.7)       | 32,063<br>(10.3)       | 33,243<br>(10.2)       | 35,080<br>(10.1)       | 36,049<br>(10.0)       | 37,860<br>(9.9)        | 39,043<br>(9.8)        |
| 55-59        | 39,833<br>(14.5)       | 42,140<br>(14.3)       | 43,507<br>(14.0)       | 44,951<br>(13.8)       | 46,174<br>(13.4)       | 47,384<br>(13.1)       | 49,119<br>(12.9)       | 50,468<br>(12.7)       |
| 60-64        | 42,231<br>(15.4)       | 46,458<br>(15.8)       | 50,187<br>(16.1)       | 53,045<br>(16.3)       | 56,747<br>(16.4)       | 59,059<br>(16.3)       | 61,020<br>(16.0)       | 63,304<br>(15.9)       |
| 65-69        | 41,038<br>(15.0)       | 43,357<br>(14.8)       | 45,925<br>(14.7)       | 47,328<br>(14.6)       | 51,427<br>(14.9)       | 55,209<br>(15.3)       | 60,056<br>(15.8)       | 64,124<br>(16.2)       |
| 70-74        | 37,359<br>(13.6)       | 40,155<br>(13.7)       | 42,922<br>(13.8)       | 44,155<br>(13.6)       | 46,068<br>(13.3)       | 47,329<br>(13.1)       | 48,787<br>(12.8)       | 50,920<br>(12.8)       |
| 75-79        | 24,996<br>(9.1)        | 27,241<br>(9.3)        | 30,523<br>(9.8)        | 32,103<br>(9.9)        | 34,926<br>(10.1)       | 37,129<br>(10.3)       | 39,243<br>(10.3)       | 40,946<br>(10.3)       |
| 80-84        | 11,356<br>(4.1)        | 13,362<br>(4.5)        | 15,093<br>(4.8)        | 16,484<br>(5.1)        | 18,459<br>(5.3)        | 20,367<br>(5.6)        | 21,998<br>(5.8)        | 24,058<br>(6.1)        |
| 85+          | 4,708<br>(1.7)         | 5,507<br>(1.9)         | 6,465<br>(2.1)         | 6,901<br>(2.1)         | 8,351<br>(2.4)         | 9,430<br>(2.6)         | 10,647<br>(2.8)        | 12,024<br>(3.0)        |
| Mean (SD)    | <u>62.4</u><br>(12.0)  | <u>62.6</u><br>(12.1)  | <u>63.0</u><br>(12.1)  | <u>63.1</u><br>(12.1)  | <u>63.3</u><br>(12.2)  | <u>63.5</u><br>(12.2)  | <u>63.7</u><br>(12.3)  | <u>63.9</u><br>(12.3)  |
|              | 2009                   | 2010                   | 2011                   | 2012                   | 2013                   | 2014                   | 2015                   | 2016                   |

Formatted: Right: 0.07"

Formatted Table

Formatted: Centered

| NHSO Regions                      |                  |                  |                  |                  |                  |                  |                  |                  |
|-----------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| 1. Chiang <del>m</del> Mai        | 19,572<br>(7.1)  | 21,232<br>(7.2)  | 22,492<br>(7.2)  | 23,021<br>(7.1)  | 23,995<br>(6.9)  | 25,160<br>(7.0)  | 26,715<br>(7.0)  | 28,366<br>(7.1)  |
| 2. Phitsanulok                    | 14,631<br>(5.3)  | 15,857<br>(5.4)  | 16,760<br>(5.4)  | 18,195<br>(5.6)  | 19,024<br>(5.5)  | 19,455<br>(5.4)  | 20,411<br>(5.4)  | 20,937<br>(5.3)  |
| 3. Nakhon <del>s</del> Sawan      | 13,592<br>(5.0)  | 15,699<br>(5.3)  | 16,764<br>(5.4)  | 17,646<br>(5.4)  | 17,999<br>(5.2)  | 18,288<br>(5.1)  | 18,974<br>(5.0)  | 19,865<br>(5.0)  |
| 4. Saraburi                       | 23,401<br>(8.5)  | 25,965<br>(8.8)  | 26,257<br>(8.4)  | 25,344<br>(7.8)  | 26,249<br>(7.6)  | 27,420<br>(7.6)  | 28,995<br>(7.6)  | 30,772<br>(7.8)  |
| 5. Ratchaburi                     | 27,208<br>(9.9)  | 28,203<br>(9.6)  | 30,047<br>(9.6)  | 29,901<br>(9.2)  | 31,538<br>(9.1)  | 32,479<br>(9.0)  | 33,122<br>(8.7)  | 34,033<br>(8.6)  |
| 6. Rayong                         | 22,439<br>(8.2)  | 24,207<br>(8.2)  | 26,634<br>(8.5)  | 27,231<br>(8.4)  | 28,588<br>(8.3)  | 29,743<br>(8.2)  | 30,891<br>(8.1)  | 33,143<br>(8.4)  |
| 7. Khon <del>k</del> Kaen         | 27,623<br>(10.1) | 30,320<br>(10.3) | 32,205<br>(10.3) | 34,357<br>(10.6) | 36,748<br>(10.6) | 39,207<br>(10.8) | 40,608<br>(10.7) | 41,217<br>(10.4) |
| 8. Udon <del>t</del> Thani        | 27,032<br>(9.9)  | 28,833<br>(9.8)  | 30,200<br>(9.7)  | 30,522<br>(9.4)  | 33,339<br>(9.6)  | 35,563<br>(9.8)  | 37,644<br>(9.9)  | 38,258<br>(9.6)  |
| 9. Nakhon <del>r</del> Ratchasima | 26,587<br>(9.7)  | 27,945<br>(9.5)  | 30,292<br>(9.7)  | 33,091<br>(10.2) | 36,295<br>(10.5) | 38,139<br>(10.5) | 41,198<br>(10.8) | 44,157<br>(11.1) |
| 10. Ubon <del>r</del> Ratchathani | 20,241<br>(7.4)  | 20,368<br>(6.9)  | 22,361<br>(7.2)  | 23,425<br>(7.2)  | 25,384<br>(7.3)  | 26,835<br>(7.4)  | 29,299<br>(7.7)  | 30,886<br>(7.8)  |
| 11. Surat <del>t</del> Thani      | 14,498<br>(5.3)  | 15,659<br>(5.3)  | 16,723<br>(5.4)  | 18,423<br>(5.7)  | 19,504<br>(5.6)  | 21,075<br>(5.8)  | 21,777<br>(5.7)  | 22,817<br>(5.7)  |
| 12. Songkhla                      | 14,515<br>(5.3)  | 14,903<br>(5.1)  | 15,888<br>(5.1)  | 17,570<br>(5.4)  | 19,069<br>(5.5)  | 19,613<br>(5.4)  | 20,591<br>(5.4)  | 21,288<br>(5.4)  |
| 13. Bangkok                       | 23,001<br>(8.4)  | 24,526<br>(8.4)  | 24,984<br>(8.0)  | 26,096<br>(8.0)  | 27,968<br>(8.1)  | 28,982<br>(8.0)  | 30,362<br>(8.0)  | 31,171<br>(7.9)  |
| Total                             | 274,340          | 293,717          | 311,607          | 324,822          | 345,700          | 361,959          | 380,587          | 396,910          |

Note: The Universal Coverage Scheme (UCS) patients admitted for T2DM are the UCS beneficiaries who were admitted for type 2 diabetes mellitus (T2DM) between 2009 and 2016. The number of UCS patients was counted as one in a year. That is, a UCS patient who was admitted for T2DM for multiple times in a year was counted as one in that year. If the same patient was admitted for T2DM in another year, he/she was counted as one again in the separate year.

1 Fig 2 shows the population pyramids of admitted cases with T2DM among the UCS beneficiaries in  
2 Thailand in 2009 and 2016. The female admission rates were persistently higher than that of males both  
3 in 2009 and 2016. The sex ~~inequaldisparities~~ in the admission rates widened between their 30s and  
4 ~~early-870s~~. In 2009, the admission rates of both sexes started increasing in their late 30s, ~~females~~  
5 reached a peak at the ages of 70 to 74 and males at the ages of 75 to 79, and then ~~both~~ declined. ~~In 2016,~~  
6 ~~both sexes reached a peak at the ages of 75-79~~. Although the trend was similar ~~in the two years~~, the  
7 admission rates were persistently much higher and the overall increase occurred in older ages in 2016.

8 **Fig 2. Population pyramids of admitted cases with type 2 diabetes mellitus (T2DM)**  
9 **among the Universal Coverage Scheme ~~patientbeneficiaries~~ in Thailand in 2009 and 2016**

10 ~~Note: T2DM admission rates are per 1,000 population, standardized by age and sex using the 2009~~  
11 ~~national UCS population.~~

12 Fig 3 presents the number of patients, the number of admissions and the admission rates of T2DM and  
13 those with the ~~five~~six major complications: CKD, MI, ~~stroke~~cerebrovascular diseases, retinopathy,  
14 cataract and ~~amputation~~foot amputation from 2009 to 2016 in Thailand. ~~The number of admissions~~  
15 ~~refers to how many times the UCS patients were admitted for type 2 diabetes mellitus with or without~~  
16 ~~complications in each year, whereas the number of patients refers to how many patients were admitted~~  
17 ~~in the year. A patient could be admitted for multiple times in a year.~~ Overall, there was a linearly  
18 increased trend in ~~the number of~~ T2DM admission ~~rates~~ with ~~by~~ about 55.29% ~~annually increase per~~  
19 ~~year~~. Among the T2DM admissions, 294.90% was associated with CKD in 2009-2016, and the T2DM

1 admission rates with CKD also ~~which also had a~~ positive linear trend ~~by of 510.90% increase in the~~  
2 ~~number of admissions pper year. Of other four complications, a~~Admission rates of T2DM with CKD  
3 ~~were 3.5/1000, associated with strokecerebrovascular diseases 1.1/1000, cataract 0.5/1000, MI 0.4/1000,~~  
4 ~~and retinopathy MI and foot amputation 0.2/1000 population, respectivelyretinopathy/cataracts were~~  
5 ~~comparable of around 0.4 per 1,000 population, while that with stroke and amputation were~~  
6 ~~approximately 4 times less i.e. about 0.1 per 1,000 population.~~ It is noted that the increasing trends of  
7 T2DM admission with ~~CKD and strokecerebrovascular diseases MI and amputation a~~were visually  
8 observable, ~~while those . The T2DM admission rates with MI, strokes and~~  
9 ~~retinopathy/cataract~~retinopathy and foot amputation were rather subtle, and that with ~~scataract wa~~were  
10 ~~both relatively~~ stable.

11 **Fig 3. The number of patients, the number of admissions and admission rates of type 2 diabetes**  
12 **mellitus with and without the five major complications in Thailand from 2009 to 2016**

13 Legend:   
14  Number of patients  
15  Number of admissions  
16  Admission rates

17 Note: The number of admissions refers to how many times the Universal Coverage Scheme (UCS) patients were admitted  
18 for type-2 diabetes mellitus (T2DM) with or without complications in each year, whereas the number of patients refers to  
19 how many T2DM patients were admitted in the year. A patient could be admitted for multiple times in a year. The admission  
20 rate is the number of admissions divided by the number of the Universal Coverage (UC) schemeS population patients in the  
21 year standardized by sex and age of the 2009 UCS scheme 2009 population beneficiaries. The scale for all T2DM admission  
22 rates is different from others as it went up to 17.3/1000 in 2016.

1 Table 2 presents the results of the time series regressions to estimate temporal trend of admissions  
 2 showed that all types of T2DM admissions except that with cataract had a significant and positive  
 3 temporal trend.

4 **Table 2. Time series regressions parameters of temporal trend analysis for admissions**

| <u>Parameters</u>   | <u>Estimate</u> | <u>SE</u> | <u>z value</u> | <u>p value</u> |
|---|-----------------|-----------|----------------|----------------|
| <u>All DM admissions</u>                                  |                 |           |                |                |
| $\beta_0$ : intercept                                     | -4.460529       | 0.006002  | -743.16        | p < 0.001      |
| $\beta_1$ : time point                                    | 0.050566        | 0.001187  | 42.61          | p < 0.001      |
| <u>DM with CKD admissions</u>                             |                 |           |                |                |
| $\beta_0$ : intercept                                     | -6.108389       | 0.009446  | -646.64        | p < 0.001      |
| $\beta_1$ : time point                                    | 0.095675        | 0.001861  | 51.41          | p < 0.001      |
| <u>DM with MI admissions</u>                              |                 |           |                |                |
| $\beta_0$ : intercept                                     | -8.11538        | 0.02155   | -376.58        | p < 0.001      |
| $\beta_1$ : time point                                    | 0.07541         | 0.00424   | 17.78          | p < 0.001      |
| <u>DM with stroke/cerebrovascular diseases admissions</u> |                 |           |                |                |
| $\beta_0$ : intercept                                     | -7.251687       | 0.009935  | -729.93        | p < 0.001      |
| $\beta_1$ : time point                                    | 0.084358        | 0.001941  | 43.47          | p < 0.001      |
| <u>DM with cataract admissions</u>                        |                 |           |                |                |
| $\beta_0$ : intercept                                     | -7.604557       | 0.046891  | -162.175       | p < 0.001      |
| $\beta_1$ : time point                                    | 0.015244        | 0.009283  | 1.642          | 0.101          |
| <u>DM with retinopathy admissions</u>                     |                 |           |                |                |
| $\beta_0$ : intercept                                     | -8.941096       | 0.028458  | -314.181       | p < 0.001      |
| $\beta_1$ : time point                                    | 0.049766        | 0.005599  | 8.888          | p < 0.001      |
| <u>DM with amputation admissions</u>                      |                 |           |                |                |
| $\beta_0$ : intercept                                     | -8.955374       | 0.023377  | -383.09        | p < 0.001      |
| $\beta_1$ : time point                                    | 0.050946        | 0.004584  | 11.12          | p < 0.001      |

5 Note: SE: Standard error, CI: Confidence interval, DM: Diabetes mellitus, CKD: Chronic kidney  
 6 disease, MI: Myocardial infarction



1 Fig 4 presents ~~comparison in~~ SARs of T2DM and its complications in the NHSO 13 Regions in 2009  
2 and 2016 (~~see Supplementary table 1 for 2009 and Supplementary table 2 for 2016 for exact values~~).  
3 The SARs of T2DM were high in central and northeastern regions: 1.20/1000 in Region 4 (Saraburi),  
4 1.22/1000 in Region 5 (Ratchaburi), 1.31/1000 in Region 7 (Khon Kaen) and 1.22/1000 in Region 8  
5 (Udon Thani) ~~were in 2009~~, but they all declined close to the national average by 2016 except Region  
6 7 that further increased to 1.44/1000. In the same period, ~~particularly high in Region 3 (Nakhonsawan)~~  
7 the SARs of T2DM increased from 0.88 to 1.05/1000 in Region 9 (Nakhon Ratchasima), and declined  
8 ~~from 1.00 to 0.83/1000 in Region 13 (Bangkok) (1.5/1000) and Region 2 (Phitsanulok) (1.5/1000) in~~  
9 ~~2009 and the admission rates in Region 3 (Nakhonsawan) further increased from 2009 to 2016~~  
10 ~~(1.8/1000)~~. The SARs of T2DM with CKD were high in northeastern regions in 2009: 1.79/1000 in  
11 Region 7 (Khon Kaen), 1.58/1000 in Region 8 (Udon Thani) and 1.64/1000 in Region 10 (Ubon  
12 Ratchathani), but they all declined to 1.70/1000, 1.45/1000 and 1.60/1000 by 2016, respectively. On  
13 the other hand, the SAR of T2DM with CKD in Region 9 increased from 0.86 to 1.05/1000 in the same  
14 period. The SARs of T2DM with MI was high in Bangkok and central regions in 2009: 1.60/1000 in  
15 Region 4 and 1.69/1000 in Region 13 (Bangkok), but they both declined to 1.43/1000 and 1.27/1000 by  
16 2016, respectively. The SAR of T2DM with MI in Region 7 increased from 0.88 in 2009 to 1.01 in  
17 2016. The SARs of T2DM with ~~stroke~~ cerebrovascular diseases were also high in Bangkok and central  
18 regions in 2009: 1.46/1000 in Region 4 (Saraburi), 1.35/1000 in Region 5 (Ratchaburi), 1.34/1000 in  
19 Region 6 (Rayong) and 1.90/1000 in Region 13 (Bangkok), but they all declined to 1.25/1000.

1 1.17/1000, 1.30/1000 and 1.21/1000 by 2016, respectively. The SARs of T2DM with  
2 stroke/cerebrovascular diseases increased in Region 7 and 9 between 2009 and 2016, from 0.83 to  
3 1.03/1000 and 0.65 to 1.11/1000, respectively. The SAR of T2DM with retinopathy in Region 13 was  
4 4 times higher than the national average in 2009. Although it declined to 2.77/1000 by 2016, it was still  
5 much higher than other regions. In the same period, the SARs of T2DM with retinopathy increased in  
6 Region 8 and 11 (Surat Thani), from 0.43 to 1.11/1000 and 0.52 to 1.00/1000, respectively. The SARs  
7 of T2DM with cataract were high in Bangkok and central regions in 2009: 2.35/1000 in Region 4,  
8 1.95/1000 in Region 5 and 1.64/1000 in Region 13, but they all declined to 1.40/1000, 1.33/1000 and  
9 1.25/1000 by 2016, respectively. Whereas, the SARs of T2DM with cataract increased from 0.76 to  
10 1.13/1000 in Region 11 in the same period. The SARs of T2DM with foot amputation was high in  
11 Bangkok and central and northeastern regions in 2009: 1.21/1000 in Regions 4, 1.35/1000 in Region 7,  
12 1.24/1000 in Region 8 and 1.45/1000 in Region 13. By 2016, the SARs of T2DM with foot amputation  
13 in Regions 4 and 13 declined to 0.97/1000 and 1.16/1000, respectively, while those further increased in  
14 Region 7 and 8 to 1.61/1000 and 1.43/1000, respectively.

15 **Fig 4. Comparison of age- and sex- standardized admission ratio of type 2 diabetes mellitus and**  
16 **its complications in the NHSO Regions in 2009 and 2016**

17 Note: The standardized admission ratio (SAR) of type 2 diabetes mellitus (T2DM) and its complications were shown in white  
18 if it is the national average. The color changes into red if SAR is higher than the national average, and gray if it is lower than  
19 the national average. The scale for SARs of T2DM with retinopathy is different from others: it continues up to 5.0 because  
20 SAR of T2DM with retinopathy in Bangkok was substantially higher than other regions in 2009.

21

## 1 **Discussion**

2 A linearly increased trend of T2DM admission rates and that with the ~~six~~five major diabetic  
3 complications were found from 2009 to 2016 in Thailand. Female admission rates were persistently  
4 higher than that of males. In 2016, overall increase in the T2DM admission rates was observed among  
5 the older ages relative to that in 2009. ~~Although geographical inequalities~~ ~~The geographic difference in~~  
6 the T2DM admission ~~rates~~ratios were ~~also~~ found, ~~the reduced trend in the inequalities was also observed~~  
7 ~~between 2009 and 2016.~~

8  
9 ~~The observed sex disparities in frequency of the T2DM admissions were consistent with the National~~  
10 ~~Health Examination Surveys [2] and an assessment on quality of care among patients diagnosed with~~  
11 ~~T2DM and hypertension, which presented that females in Bangkok were 1.13 times more likely to have~~  
12 ~~HbA1C level of higher than 9.0% [21]. Biology might play a part in observed sex disparities as women~~  
13 ~~typically transition from prediabetes to diabetes with a worse cardiovascular risk profile and a higher~~  
14 ~~BMI than men. However, psychosocial factors, such as health-seeking behavior and provision of health~~  
15 ~~care, play more important part in the differences, which can be addressed through changes in policy~~  
16 ~~and health-care delivery [22]. It should be noted that high admission rate does not necessarily mean~~  
17 ~~high prevalence of the disease, as previous studies showed higher percentage of undiagnosed diabetes~~  
18 ~~[2] and slightly higher fasting plasma glucose among males in Thailand [23].~~

19

1 While the number of patients, the number of admissions and admission rates of T2DM steadily  
2 increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates,  
3 which were estimated using the national UCS population of 2009 as the standard population, (12.1 in  
4 2009 and 15.0 in 2016, results not shown) ~~were~~ rather gradual as compared with the numbers of crude  
5 admissions rates (12.1 in 2009 and 17.3 in 2016) ~~and patients and the number of admissions~~. This result  
6 suggests that the increase in the T2DM admission rates ~~is largely due to~~ is partly due to the increased  
7 and aged population of the country ~~the increased and aged population of the country~~. Although further  
8 studies are required, it could imply that ~~This finding further suggests that Thailand~~ the country may face  
9 the greater burden of T2DM ~~in the future if the trend of population growth and aging will continue~~ in  
10 the country.

11  
12 The T2DM admission rates reached a peak at the ages of 70s to 79 and then declined in 2009 and 2016  
13 presumably due to premature death of the T2DM patients. The shifted trend of the peak age toward  
14 elderly among females between 2009 and 2016 can be explained by the fact that the T2DM patients had  
15 aged and their longevity had been extended over the eight years [24]. This trend further implies the  
16 need of increased costs of providing diabetes-related care as older adults with diabetes is clearly more  
17 complicated with multiple coexisting medical conditions, particularly macrovascular complications  
18 such as acute myocardial infarction and stroke ~~cerebrovascular diseases~~ and end-stage renal disease [25].

1 Age also affects the potential risks of overtreatment of hyperglycemia in the hospital, which often leads  
2 to longer ~~hospitalization~~ hospitalization, higher medical costs ~~+~~ and increased mortality [26][27].

3  
4 Among the ~~six-five~~ diabetic complications, CKD showed the most ~~conspicuous-significant~~ increase  
5 ~~between~~ ~~from~~ 2009 ~~to~~ and 2016. Although Thailand has launched the “Thailand Healthy Lifestyle  
6 Strategy 2011-2020 Plan,” [28] to ~~reduce~~ ~~decrease~~ the prevalence, complications, disability, mortality  
7 and cost of non-communicable diseases including diabetes, national screening and prevention program  
8 has not yet been in place [4]. Additionally, renal replacement therapy including renal and peritoneal  
9 dialysis and kidney transplantation requires the UCS patients with a co-payment [29], which may have  
10 inhibited some of them from accessing to proper care. Thailand should take this trend seriously as this  
11 type of complication is associated with a substantial burden in terms of mortality, morbidity and  
12 healthcare cost as it often requires costly and long-term care including dialysis. To prevent progression  
13 of CKD stage, the country should ~~strengthen~~ ~~consider~~ an effective measure, such as glyated  
14 hemoglobin control (HbA1c)  $\leq 7.0\%$  [21~~30~~], as instructed in the Clinical Practice Recommendation  
15 for the Evaluation and Management of Chronic Kidney Disease in Adults 2015 [30]. This study also  
16 found that the number of admitted cases with CKD were ~~-1.7 times greater~~ ~~more than twice as~~ ~~than~~ the  
17 number of patients. This indicates that many of the patients with diabetic complication of CDK were  
18 readmitted, and implies that there might be unmet needs of inpatient care for the T2DM patients with

1 CKD. Further study should be conducted to investigate the reasons behind the frequent readmissions  
2 and take measures to meet the needs of the patients.

3  
4 While the SARs of T2DM were higher in Bangkok and central regions relative to other regions in 2009,  
5 except those with CKD and partly foot amputation, they declined in most of the regions by 2016.  
6 Additionally, there was an overall trend of SAR reduction in Bangkok and central regions, where human  
7 and financial resources were traditionally concentrated, and increase in northeastern regions, where the  
8 resources were traditionally scarce, over the eight years [9, 31]. This trend indicates Thailand's  
9 successful health reform by reducing geographical inequalities in inpatient care, which might be a result  
10 of equitably redistributed health professionals, health infrastructure development and rural retention  
11 policies over the past four decades [32].

12  
13 On the other hand, the persistently high SAR of T2DM with retinopathy in Bangkok is presumably due  
14 to high density of specialists as half of 1,500 ophthalmologists, including 200 retinal specialists, practice  
15 in Bangkok [33].

16  
17 ~~The T2DM admission rate was particularly high in Region 2 (Phitsanulok) and Region 3~~  
18 ~~(Nakhonsawan). Although high hospital admission rate could mean that the people with T2DM are~~  
19 ~~receiving necessary healthcare, investigation should be carefully conducted to accurately understand~~

1 ~~the situations in these regions. The~~ The persistently high SAR of T2DM with CKD in northeastern  
2 ~~regions was consistent with a previous study and partly attributed to high prevalence of CKD in~~  
3 ~~northeastern regions (10.8%) relative to other regions (north 8.9%, south 8.1% and Bangkok 6.2%) [34],~~  
4 ~~but partly to an association with lower density of physicians and rurality of the region [13]. The density~~  
5 ~~of physicians in northeastern regions is the lowest in the country [32], as low as seven times lower than~~  
6 ~~Bangkok [9]. It is reasonable to assume that in a region where physicians are scarce, T2DM patients~~  
7 ~~with CKD are unlikely to receive timely, thorough and effective treatment, and consequently deteriorate~~  
8 ~~in conditions. This assumption might explain the high readmission rates of T2DM with CDK, and the~~  
9 ~~highest mortality rates due to diabetes in northeastern regions as found in another study [12]. Moreover,~~  
10 ~~rurality of the northeastern regions, where 71.0% of the population reside in rural setting (north 65.6%,~~  
11 ~~south 66.5% and Central 54.5%) [35], might have halted them from accessing adequate primary care.~~  
12 ~~A previous study found a strong association between the high SAR of diabetes and rurality as the rural~~  
13 ~~population tends to have lack of public transport alternatives and poor health literacy with less education~~  
14 ~~which often limit accessibility to health care. The study also suggested that the percentage of patients~~  
15 ~~who had received up to secondary education was lower in rural districts by approximately 10% [13].~~  
16 ~~most distinctive increase in T2DM diabetes admission rates were seen in the northeastern part of the~~  
17 ~~country, namely Region 7 (Khon Kaen), Region 9 (Nakhon Ratchasima) and Region 10 (Ubon~~  
18 ~~Ratchatani). This geographic trend was consistent with the previous study which found high mortality~~  
19 ~~rates due to diabetes in these regions [12]. The increased admission rates could infer increased capacity~~

1 of health facility. However, it is not the case in these regions because of the high diabetes specific  
2 mortality rate. As the majority of the population in these regions presumably reside in rural areas, urban  
3 life style, a conventional risk factor of T2DM, cannot be applied to the population. Therefore, there is  
4 a need for substantial assessment for associated risk factors in Thai rural areas and quality of healthcare  
5 provided to the people in the regions.

6  
7  
8 Inaccessibility to the outpatient data and absence of information indicating direct causality between  
9 diabetes and complicated conditions were the major limitations of this study. For the first limitation, it  
10 is important to monitor the long-term trends of diabetic morbidity starting at onset of disease,  
11 accessibility and quality of outpatient and inpatient care, and health outcome including mortality to  
12 assess the quality of T2DM healthcare in the country. Besides, community involvement in diabetic care  
13 should be also carefully monitored, as approximately 77.0% of cost is involved in non-medical activities  
14 [36], and community-based screening, study and health promotion would be increasingly important for  
15 diabetic care [4]. In this study, we looked at the trend of the inpatient care and tried to capture that of a  
16 series of healthcare, ~~but-~~ future study should carefully assess the situations of accessibility and quality  
17 of T2DM outpatient care, and coordination of outpatient and inpatient care for the most cost-  
18 effective T2DM healthcare policies in Thailand.



1 For the second limitation, we regarded the complications as if they were directly caused by T2DM,  
2 when we found T2DM as either principle or secondary diagnosis and one or more of the major  
3 complications in an individual record of the hospital admission database since it was the only available  
4 information.

5

6 ~~Although~~ Thailand has achieved great improvement in health care reform invested on equitable health  
7 finance and increased total budget for health expenditures, ~~particularly~~ in T2DM and its complications,

8 ~~reduction of the T2DM burden has not been achieved.~~ It is time for the country to carefully identify the  
9 risk factors and regions in particular needs of care for T2DM and its complications, and plan on the

10 effective and efficient health care which would not leave no one behind in the country.

## 1 **Acknowledgements**

2 Our special thanks go to the Bureau of Information technology and Bureau of Health information and  
3 Outcome Evaluation, NHSO. They supported and provided us with the hospital data for this research.

4

## 5 **Contributors**

6 TL acquired the data, conceived of and designed the study, and drafted the final manuscript. HT and

7 HN analysed the data, interpret and discuss the results, and drafted the final manuscript. SN, AL and

8 NS designed the statistical framework and supported data analysis. AL and NS confirmed the quality

9 of data and the study design. VC, TL, KS and HM took responsibility for the integrity of the data and

10 the accuracy of the data analysis and will oversee the study. All the authors made critical revisions to

11 the manuscript for important intellectual content, gave final approval of the manuscript, and will support

12 the interpretation and discussion of findings.

13

## 14 **Data reporting**

15 All ~~patient records were fully anonymized before we accessed. The relevant~~ UCS data are available

16 upon request to the National Health Security Office, Thailand, with the research outline and the details

17 of the required data.

## 1 **References**

- 2 1. Cho N-H, ~~Show~~ JE, Karuranga S, Huang Y, da Rocha Fernandes J-D, Ohlrogge A-W, ~~et al.~~ IDF  
3 Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.  
4 Diabetes Res Clin Pract. 2018; ~~138:~~ ~~Epub 26 February, 2018.~~ ~~271-281.~~
- 5 2. Reutrakul S, Deerochanawong C. Diabetes in Thailand: Status and Policy. Curr Diab Rep. 2016  
6 Mar;16(3):28.
- 7 3. World Health Organization. ~~WH~~ Global Report on Diabetes. ~~2016~~-Geneva: WHO Press; 2016.
- 8 4. ~~Deerochanawong C, Ferrario A. Diabetes management in Thailand: a literature review of the~~  
9 ~~burden, costs, and outcomes. Global Health. 2013 Mar 14;9:11. doi: 10.1186/1744-8603-9-11.~~  
10 ~~Chaicharn D, Ferrario A. Diabetes management in Thailand: a literature review of the burden,~~  
11 ~~costs, and outcomes. Globalization and Health. 2013;9(11).~~
- 12 5. World Health Organization. Thailand. Diabetes country profiles\_2016. Available from:  
13 [https://www.who.int/diabetes/country-profiles/tha\\_en.pdf?ua=1](https://www.who.int/diabetes/country-profiles/tha_en.pdf?ua=1)
- 14 6. Rawdaree P, Deerochanawong C, Chetthakul T, Benjasuratwong Y, Kosachunhanun N,  
15 Leelawatana R, et al. Thailand Diabetes Registry (TDR) project: Clinical status and long term  
16 vascular complications in diabetic patients. J Med Assoc Thai. 2006; ~~89~~ (Suppl 1): S1-9.
- 17 7. Aekplakorn W, Puckchareon H, Thaikla K, Satheannoppakao W. The National Health  
18 Examination Survey V. Bangkok: Health Systems Research Institute; 2016.

- 1 8. Worldometers. 2019. Available from: <https://www.worldometers.info/world->  
2 [population/thailand-population/](https://www.worldometers.info/world-population/thailand-population/) ~~[cited 2019 August 5]~~.
- 3 9. ~~World Health Organization~~. Primary health care systems (PRIMASYS): case study from Thailand,  
4 abridged version. Geneva: World Health Organization; 2017. ~~Licence: CC BY-NC-SA 3.0 IGO~~
- 5 10. National Health Security Office. NHSO UC Information. ~~Bangkok~~: Executive Information  
6 System; 2019.
- 7 11. Tangatharoensathien V, Limwattaranon S, Patcharanarumol W, Thammatacharee J. Monitoring  
8 and evaluating progress towards universal health coverage in Thailand. *PLoS Med*.  
9 2014;11(9):e1001726. doi:10.1371/journal.pmed.1001726.
- 10 12. Aungkulanon S, Tangcharoensathien V, Shibuya K, Bundhamcharoen K, ~~and~~  
11 Chongsuvivatwong V. Post universal health coverage trend and geographical inequities of  
12 mortality in Thailand. ~~International Journal for Equity in Health~~. 2016;15(190). doi: 10.1186/s  
13 12939-016-0479-5.
- 14 13. Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the  
15 district level and health outcomes: a case study of diabetes mellitus care in Thailand. *Risk Manag*  
16 *Healthc Policy*. 2018; 11, 199-208
- 17 14. Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates  
18 and Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage  
19 Scheme Data. *AJP Rep*. 2019; 9(4): 328-336.

- 1 ~~14-15.~~ Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasuratwong Y, et  
2 al. Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients. J  
3 Med Assoc Thai. 2006;89 Suppl 1:S60-5. Epub 2007/08/25. PubMed PMID: 17715835.
- 4 ~~15-16.~~ Ministry of Public Health. International Classification of Diseases 10th Revision (ICD10).  
5 2016. Available from: <http://www.thcc.or.th/ebook1/2016/mobile/index.html#p=1> ~~[cited 2019~~  
6 ~~March 12]~~.
- 7 ~~16-17.~~ Thai CaseMix Center. ICD-9-CM 2015 Classification of Procedure. 2015. Available from:  
8 <http://www.tcmc.or.th/main/index.php/153-icd9cm2015> ~~[cited 2019 March 12]~~.
- 9 ~~17-18.~~ R Core Team. R: A language and environment for statistical computing. R Foundation for  
10 Statistical Computing, Vienna, Austria. 2019. Available from: <https://www.R-project.org/> ~~[cited~~  
11 ~~2019 July 3]~~.
- 12 ~~18-19.~~ Pebesma E, Bivand R, Racine E, Sumner M, et al. Simple Features for R. July 3, 2019. [\[cited](#)  
13 [2019 July 3\]](#). Available from: <https://cran.r-project.org/web/packages/sf/sf.pdf> ~~[cited 2019 July~~  
14 ~~3]~~.
- 15 ~~20.~~ Wickham H, Chang W, Henry L, Pedersen TL, et al. Create Elegant Data Visualisations Using the  
16 Grammar of Graphics. Package 'ggplot2.' June 14, 2019. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/ggplot2/ggplot2.pdf)  
17 [project.org/web/packages/ggplot2/ggplot2.pdf](https://cran.r-project.org/web/packages/ggplot2/ggplot2.pdf) ~~[cited 2019 July 3]~~.
- 18 ~~21.~~ [Sonthon P, Promthet S, Changsirikulchai S, Rangsin R, Thinkhamrop B, Rattanamongkolgul S, et](#)  
19 [al. The impact of the quality of care and other factors on progression of chronic kidney disease in](#)

1 [Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study. PLoS One. 2017 Jul](#)  
2 [28;12\(7\):e0180977. doi: 10.1371/journal.pone.0180977.](#)

3 [22. Sex disparities in diabetes: bridging the gap. Lancet Diabetes Endocrinol: Editorial. 2017;](#)  
4 [5\(11\):839](#)

5 ~~19.~~ [Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S,](#)  
6 [et al. The Prevalence and Management of Diabetes in Thai Adults. Diabetes Care. 2003; 26\(10\):](#)  
7 [2758-2763. DOI: 10.2337/diacare.26.10.2758.](#)

8 ~~23. United Nations, Department of Economic and Social Affairs, Population Division. World~~  
9 ~~Population Aging 2017. 2017.~~

10 ~~20-24.~~ [United Nations, Department of Economic and Social Affairs, Population Division. World](#)  
11 [Population Ageing 2017 - Highlights. New York: United Nations; 2017](#)

12 ~~24-25.~~ [Gregg EW, Li Y, Wang J, Burrows NR, Ali MA, Rolka D, et al. Changes in diabetes-related](#)  
13 [complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–1523.](#)

14 ~~22-26.~~ [Umpierrez GE, Pasquel FJ. Management of inpatient hyperglycemia and diabetes in older](#)  
15 [adults. Diabetes Care. 2017;40:509–517.](#)

16 ~~23-27.~~ [Alagiakrishnan K, Mereu L. Approach to managing hypoglycemia in elderly patients with](#)  
17 [diabetes. Postgrad Med 2010;122:129–137](#)

- 1 ~~24-28.~~ Ministry of Public Health. Thailand healthy lifestyle strategic plan 2011-2020. ~~Bangkok,~~  
2 ~~Thailand: The War Veterans Organizations of Thailand; 2011. p. 58. Available from:~~  
3 ~~https://dokumen.tips/documents/thailand-healthy-lifestyle-strategic-plan-2011-2020.html.~~
- 4 ~~25-29.~~ Treerutkuarkul A. Thailand: health care for all, at a price. Bull World Health Organ.  
5 2010;88(2):84-85.
- 6 ~~26. Sathon P, Promthet S, Changsirikulchai S, Rangsin R, Thinkhamrop B, Rattanamongkolgul S, et~~  
7 ~~al. The impact of the quality of care and other factors on progression of chronic kidney disease in~~  
8 ~~Thai patients with Type 2 Diabetes Mellitus: A nationwide cohort study PLoS One. 2017;12(7):~~  
9 ~~27.1. Sex disparities in diabetes: bridging the gap. Lancet Diabetes Endocrinol: Editorial. 2017;~~  
10 ~~5(11):839~~
- 11 ~~28-30.~~ Chittinan A, Eiam-ong S, Kantachuesiri S, Chailimpamontri W. Clinical Practice  
12 Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults  
13 2015. ~~(Internet)~~-1<sup>st</sup> ed. Bangkok: ~~T~~The ~~N~~nephrology Society of Thailand; 2015. ~~9p.~~ Available  
14 ~~from:~~ [http://www.nephrothai.org/images/10-11-](http://www.nephrothai.org/images/10-11-2016/Final_%E0%B8%84%E0%B8%A1%E0%B8%AD_CKD_2015.pdf)  
15 [2016/Final\\_%E0%B8%84%E0%B8%A1%E0%B8%AD\\_CKD\\_2015.pdf](http://www.nephrothai.org/images/10-11-2016/Final_%E0%B8%84%E0%B8%A1%E0%B8%AD_CKD_2015.pdf)
- 16 ~~31.~~ Lindelow M, Hawkins L, Osornprasop S. Government spending and central-local relations in  
17 Thailand's health sector. Washington DC: The International Bank for Reconstruction and  
18 Developemnt/The World Bank; 2012.

- 1 [32. Witthayapipopsakul W, Cetthakrikul N, Suphanchaimat R, Noree T, Sawaengdee K. Equity of](#)  
2 [health workforce distribution in Thailand: an implication of concentration index. Risk Manag](#)  
3 [Healthc Policy. 2019;12:13-22.](#)
- 4 [33. Ruamviboonsuk P, Krause J, Chotcomwongse P, Sayres R, Raman R, Widner K, et al. Deep](#)  
5 [learning versus human graders for classifying diabetic retinopathy severity in a nationwide](#)  
6 [screening program. npj Digit Med. 2019; 2\(25\).](#)
- 7 [34. Ong-ajyooth L, Vareesangthip K, Khonputsa P, Aekplakorn W. Prevalence of chronic kidney](#)  
8 [disease in Thai adults: a national health survey. BMC Nephrology. 2009; 10\(35\).](#)
- 9 ~~29. National Statistical Office, Kingdom of Thailand. The 2010 Population and Housing Census.~~  
10 ~~Bangkok: National Statistical Office; 2012.~~~~Ong-ajyooth, L., Vareesangthip, K., Khonputsa, P. et~~  
11 ~~al. Prevalence of chronic kidney disease in Thai adults: a national health survey. BMC Nephrol~~  
12 ~~10, 35 (2009).~~
- 13 [35.](#)
- 14 ~~Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupajit K, Panpuwong N, et al.~~  
15 ~~Cost of diabetes and its complications in Thailand: a complete picture of economic burden. Health~~  
16 ~~Soc Care Community. 2011; 19(3), 289–298.~~



- 1 [30.36. Chatterjee S, Riewpaiboon A, Piyathakit D, Riewpaiboon W, Boupaikit K, Panpuwong N, et](#)
- 2 [al. Cost of diabetes and its complications in Thailand: a complete picture of economic burden.](#)
- 3 [Health Soc Care Community. 2011; 19\(2\): 289-298.](#)

1 Annalijn I Conklin  
2 Academic Editor  
3 *PLOS ONE*

6 April 2020

7 **Re: Manuscript PONE-D-19-26129**

8  
9 Dear Dr Conklin,

10  
11 I am writing to submit a revised version of the manuscript PONE-D-19-26129. We sincerely appreciate  
12 the helpful comments from you and the reviewers, and we have revised our manuscript according to  
13 their suggestions.

14  
15 Please find below the responses to the comments from you and the reviewers.

16  
17 Also, thank you for inviting us to responding to the Health Inequities and Disparities Research Call.  
18 We would appreciate if our paper is going to be part of your paper collection.

19  
20 We hope that the revised manuscript will now be acceptable for publication in PLOS ONE and look  
21 forward to your decision. Thank you very much for your consideration of this manuscript.

22  
23 Sincerely,

24  
25 Hisateru Tachimori, PhD  
26 Hisateru TACHIMORI  
27 Institute for Global Health Policy Research (iGHP)  
28 Bureau of International Health Cooperation  
29 National Center for Global Health and Medicine (NCGM)

30  
31 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655,  
32 Japan

1 **RESPONSE TO REVIEWERS**

2 We would like to thank the editor and reviewers for their helpful comments. Our responses to the  
3 comments from the editor and reviewers #1, #2 and #3 are given beneath each comment. The revised  
4 text is indented and edited in our response for ease of reference, with the section, page numbers and  
5 lines of the revised manuscript provided where necessary.

6  
7 **Response to Reviewer #1**

8 *General comments:*

9 *The selection of the patients is unclear and the presentation of the results is not clear either. This paper*  
10 *could have a great potential if presented in relation with incidence and prevalence.*

11  
12 *Major comments:*

13 *Abstract*

14 1) *Some results are only presented in the abstract. For example: “Among the five major diabetic*  
15 *complications, the average annual increase in admission rates in 2009–2016 for CKD, MI, stroke,*  
16 *cataracts, and amputation were 10.8%, 5.6%, 7.7%, 0.2%, and 6.1%, respectively.”*

17  
18 Thank you very much for pointing this out. We missed reflecting the re-written parts of the main text  
19 to the abstract. We have substantially revised the abstract this time. (Abstract, page 3-4)

20  
21 *Introduction*

22 2) *Thailand has universal health coverage since 2002. Why your study report results only from 2009?*  
23

24 Thank you very much for your observation. Although Thailand achieved UHC in 2002, we decided to  
25 use only data from 2009 onwards for our analyses since there were a number of missing values and  
26 errors in data before 2009. To make it clearer, we have added the following sentence in Materials and  
27 methods section as follows:

28  
29 “Although Thailand achieved UHC in 2002, we decided to use only data from 2009 onwards for our  
30 analyses since there were a number of missing values and errors in data before 2009 [13, 14].”  
31 (Materials and methods: Data, page 8, lines 17-19)

32  
33 3) *Why only part of the population is covered (69.9%) by the universal health coverage as mentioned*  
34 *in the introduction?*

35  
36 Thank you very much for your inquiry. Please see Introduction section (page 5 line 19 to page 6 line 3)  
37 where we explained that there are other major health protection schemes in Thailand, i.e. the Civil

1 Service Medical Benefit Scheme and the Social Security Scheme, and the Universal Coverage Scheme  
2 (UCS) is the third scheme to cover the rest of the population, so that the country can achieve UHC.

3  
4 4) *I strongly suggest to focus your paper in Thailand globally with prevalence, incidence and*  
5 *mortality if their data allow this kind of analysis and do not focus on the 13 regional offices.*  
6 *Otherwise, can you link the higher prevalence of diabetes observed in some regions to specific risk*  
7 *factors?*

8  
9 We appreciate your thoughtful suggestion. Unfortunately, the available data did not allow us to analyse  
10 prevalence, incidence and mortality of the whole population in Thailand, since our data were limited to  
11 people covered by the Universal Coverage Scheme (UCS) in Thailand. However, we have  
12 geographically covered Thailand globally as the 13 regions are all regions in the country (see Fig 1).

13  
14 5) *The last sentence of your introduction about preventive measures is not clear since you are*  
15 *exploring only hospital data and not ambulatory care data.*

16  
17 Thank you very much for your comment. As you pointed it out, we are unable to assess the current  
18 practice of preventive measures, as we did not have access to the ambulatory care data. However, we  
19 still believe we can discuss the importance of prevention to avoid unnecessary admissions and re-  
20 admissions.

## 21 22 **Methods**

23 6) *The ICD-10 codes selected for CKD are very limited. Why not including E11.2 (Type 2 diabetes*  
24 *mellitus with kidney complications)?*

25  
26 Thank you very much for your concern. We regret it was not very clear, but E11.2 (Type 2 diabetes  
27 mellitus with kidney complications) was included in our analyses as we indicated “All admitted cases  
28 whose principle and secondary diagnoses were coded as T2DM (E11.1 to E11.9)...,” (Materials and  
29 methods: Definitions of T2DM and its complications, page 9, line 9-10) meaning that we included  
30 E11.1, **E11.2**, E11.3... E11.9.

31  
32 7) *Same question with ICD-10 codes N08.3 (Glomerular disorders in diabetes mellitus)?*

33  
34 Again, thank you very much for your suggestion. We have added N08.3 to definition of diabetic  
35 complication of chronic kidney disease, as shown below.

1 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
2 with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9.” (Materials and  
3 methods: Definitions of T2DM and its complications, page 9, lines 9-11)

4  
5 8) *Why you did not include I22 (Subsequent myocardial infarction) in the MI category?*

6  
7 Thank you very much for your question. We have added I22 (Subsequent myocardial infarction) in the  
8 MI category, as shown below.

9  
10 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
11 ... MI (I21 and I22)” (Materials and methods: Definitions of T2DM and its complications, page 9, lines  
12 9-11)

13  
14 9) *Please correct your stroke codes to I60-I69.*

15  
16 Thank you very much for pointing it out. We have corrected the text as follows:

17  
18 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
19 ... cerebrovascular diseases (I60 to I69)” Materials and methods: Definitions of T2DM and its  
20 complications, page 9, lines 9-11)

21  
22 10) *Why you used ICD-9 codes for diabetic amputations?*

23  
24 We appreciate your sensible question. We used ICD-9 codes for diabetic amputations in our study  
25 because the National Health Security Office in Thailand makes payment based on ICD-9 codes with  
26 regards to amputation, and therefore the amputation records were kept based on the ICD-9 codes.

27  
28 11) *These ICD-9 codes do not seem appropriate. Please clarify their respective definitions. I*  
29 *recommend intervention codes.*

30  
31 Thank you very much for your comment and recommendation. We have carefully reviewed the ICD-9  
32 codes and revised as shown below. Meanwhile, we remained procedure codes of ICD-9 for the above  
33 reasons.

34  
35 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
36 ... or diabetic foot amputations (8410-8417) were included” Materials and methods: Definitions of  
37 T2DM and its complications, page 9, lines 9-13)

1 12) *Moreover, did the authors excluded traumatic, cancer, congenital or sepsis related amputations?*

2  
3 Thank you very much for your confirmation. It was rather difficult to exclude traumatic, cancer,  
4 congenital or sepsis related amputations with ICD-9 codes. It was the same condition for other types of  
5 complications. We indicated this condition as a limitation in our manuscript as follows:

6  
7 “... and absence of information indicating direct causality between diabetes and complicated conditions  
8 were the major limitations of this study.” (Discussion, page 23, lines 11-12)

9  
10 13) *I would give further details about the definitions of T2DM and complications. As I understand*  
11 *the manuscript, all admission cases were collected for 2009-2016 in which either T2DM and/or*  
12 *a given complication occurs as a primary or secondary reason, for the whole population of the*  
13 *UCS (T2DM or not). Here is my question: Is the presence of T2DM is evaluated using the*  
14 *presence of T2D as a primary or secondary reason for admission OR all prevalent cases of*  
15 *diabetes were included initially before assessing admission? I would clarify this point (otherwise*  
16 *the reader might think the population are not prevalent cases of diabetes).*

17  
18 We appreciate your advice. Our answer to your question is that the presence of T2DM is evaluated  
19 using the presence of T2D as a primary or secondary diagnosis (reason) for admission. Although we  
20 could not address the prevalent cases in this study, as we could only use the admission data due to the  
21 quality reasons, we added further definitions of the T2DM and its complications as shown below.  
22 Additionally, we have decided to change some definitions of T2DM and complications, and include  
23 retinopathy as the sixth diabetic complication in our study.

24  
25 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
26 with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21 and I22),  
27 cerebrovascular diseases (I60 to I69), retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8, H25.9,  
28 H26.0 to H26.4, H26.8, H26.9, and H28.0), or diabetic foot amputations (8410-8417) were included,  
29 and any other cases were excluded from this study. Stage 3 or higher stages of CKD are usually  
30 considered as diabetic complications. However, stage 1 and 2 of CKD were also included in this study  
31 because the ICD-10 code, E11.2 includes all stages of kidney complications, and thus it was impossible  
32 to separate stage 1 and 2 of CKD cases. T2DM cases with acute and subsequent MI were included in  
33 this study. While only H36.0, diabetic retinopathy was considered as a diabetic complication, all types  
34 of cataract were included as diabetic complications in this study because diabetic cataract is often  
35 misdiagnosed as other type of cataract. Diagnosis of foot amputation was considered as a diabetic  
36 complication if it was performed from the toe to above the knee.” (Materials and methods: Definitions  
37 of T2DM and its complications, page 9, lines 9 to page 10, line 2)

1 14) *Please specify how data are presented and what they represent for example, in Table 1 (rates,*  
2 *proportions, etc.). In other words, this section should be clarified with addition of specific*  
3 *definition that the authors have misclassified in the results section such as: “The number of*  
4 *admissions refers to how many times the UCS patients were admitted for T2DM with or without*  
5 *complications in each year, whereas the number of patients refers to how many patients were*  
6 *admitted in that year. A patient could be admitted multiple times in a year.”*

7  
8 Thank you very much for your important comment. We have revised the title of Table 1 and added the  
9 note underneath Table 1 as follows. We also revised Result section as shown below.

10  
11 “Table 1. Number and demographic characteristics of the Universal Coverage Scheme patients admitted  
12 for type 2 diabetes mellitus in 2009-2016” (Results, page 12-14)

13  
14 “Note: The Universal Coverage Scheme (UCS) patients admitted for T2DM are the UCS beneficiaries  
15 who were admitted for type 2 diabetes mellitus (T2DM) between 2009 and 2016. The number of UCS  
16 patients was counted as one in a year. That is, a UCS patient who was admitted for T2DM for multiple  
17 times in a year was counted as one in that year. If the same patient was admitted for T2DM in another  
18 year, he/she was counted as one again in the separate year.” (Results, page 14)

19  
20 “Table 1 presents the number and demographic characteristics of the UCS patients admitted for T2DM  
21 in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0% of the  
22 total population of 2009-2016 in Thailand.” (Results, page 12, lines 2-4)

## 23 24 **Results**

25 15) *Table 1 is not clear. It seems to be the whole population but the title mentioned with type 2*  
26 *diabetes. The description of the whole population is not the objective of this paper. Please add*  
27 *units to this corrected Table*

28  
29 Again, thank you very much for your comment. We have revised the title of Table 1 and added the note  
30 underneath Table 1 as follows. We also revised Result section as shown below.

31  
32 “Table 1. Number and demographic characteristics of the Universal Coverage Scheme patients admitted  
33 for type 2 diabetes mellitus in 2009-2016” (Results, page 12-14)

34  
35 “Note: The UCS patients admitted for T2DM are the UCS beneficiaries who were admitted for T2DM  
36 between 2009 and 2016. The number of UCS patients was counted as one in a year. That is, a UCS  
37 patient who was admitted for T2DM for multiple times in a year was counted as one in that year. If the

1 same patient was admitted for T2DM in another year, he/she was counted as one again in the separate  
2 year.” (Results, page 14)

3  
4 “Table 1 presents the number and demographic characteristics of the UCS patients admitted for T2DM  
5 in 2009-2016. The UCS population of 15 to 100 years of age represents approximately 54.0% of the  
6 total population of 2009-2016 in Thailand.” (Results, page 12, lines 2-4)

7  
8 *16) In Figures 2 and 3, please add 95% or 99% confidence intervals.*

9  
10 Thank you very much for your suggestion. We added 95% confidence intervals to Fig 2 and 3 in Results  
11 section. In Fig 3, we added the 95% CIs to admission rate, but not to the number of patients and  
12 admissions because it makes the figure too busy to add the 95% CIs to all components.

13  
14 *17) Are rates adjusted in Figure 3?*

15  
16 Thank you for your important inquiry. The rates in Figure 3 were not adjusted. In the Figure 3, we  
17 would like to focus on describing temporal trends of crude, i.e. non-adjusted, numbers and rates.

18  
19 Aside from the Figure 3, we calculated admission rates adjusted by age and sex using the national UCS  
20 population of 2009 as the standard to discuss effects of age and sex difference between years in the  
21 discussion section.

22  
23 “While the number of patients, the number of admissions and admission rates of T2DM steadily  
24 increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates,  
25 which were estimated using the national UCS population of 2009 as the standard population, (12.1 in  
26 2009 and 15.0 in 2016, *results not shown*) were rather gradual as compared with the numbers of crude  
27 admissions rates (12.1 in 2009 and 17.3 in 2016). This result suggests that the increase in the T2DM  
28 admission rates is partly due to the increased and aged population of the country.” (Discussion, page  
29 20, lines 1-6)

30  
31 *18) Please consider confidence intervals for the description of trends and correct this sentence: “The*  
32 *increasing trend of T2DM admissions with MI and amputation are visually observable.” Please*  
33 *add the relative % of increase also.*

34  
35 Thank you very much for your suggestion. We added the 95% CIs to admission rate to Fig 3 in Results  
36 section and corrected the related sentences accordingly.

37  
38 *19) This sentence is repeated twice and should be placed in the Method Section: “The number of*



1 *admissions refers to how many times the UCS patients were admitted for T2DM with or without*  
2 *complications in each year, whereas the number of patients refers to how many patients were*  
3 *admitted in that year. A patient could be admitted multiple times in a year. The admission rate is*  
4 *the number of admissions divided by the number of the UCS patients in the year, standardized by*  
5 *sex and 15 age categories in 2009.”*  
6

7 We are very sorry that it was not clear, but the description in Results section is a note of Figure 3, not  
8 part of the main text.

### 9 10 **Discussion**

11 20) *Do all data from the different regions are collected similarly or there are differences in data*  
12 *collection (missing data)? Similarly, are there important differences in the number of people*  
13 *subscribed on the UCS, differences in resources, etc.? I think these elements could be important*  
14 *to explain the differences inter-regions, if still presented.*  
15

16 Thank you very much for your observation. The data from the different regions were collected similarly.  
17 The UCS beneficiaries are those who are not covered by other major health protection schemes, i.e. the  
18 Civil Servant Medical Benefit Scheme and the Social Security Scheme and the UCS beneficiaries  
19 account for nearly 70 percent of the population. We also did not find inter-regional difference in the  
20 number of UCS beneficiaries.

21  
22 21) *I suggest comparing with additional similar studies in order to discuss your results. I suggest to*  
23 *be careful with assumptions without references, since it might lead to overinterpretation of results.*  
24

25 Thank you so much for your suggestion. We compared with the following additional 9 studies and 2  
26 reports to discuss our studies.

### 27 28 Studies

- 29 13. Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the  
30 district level and health outcomes: a case study of diabetes mellitus care in Thailand. Risk Manag  
31 Healthc Policy. 2018. 11, 199-208  
32 14. Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates and  
33 Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage Scheme  
34 Data. AJP Rep. 2019; 9(4): 328-336.  
35 22. Sex disparities in diabetes: bridging the gap. Lancet Diabetes Endocrinol: Editorial. 2017;  
36 5(11):839

- 1 23. Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S,  
2 et al. The Prevalence and Management of Diabetes in Thai Adults. *Diabetes Care*. 2003; 26(10):  
3 2758-2763. DOI: 10.2337/diacare.26.10.2758.
- 4 31. Lindelow M, Hawkins L, Osornprasop S. Government spending and central-local relations in  
5 Thailand's health sector. Washington DC: The International Bank for Reconstruction and  
6 Development/The World Bank; 2012.
- 7 32. Witthayapipopsakul W, Cetthakrikul N, Suphanchaimat R, Noree T, Sawaengdee K. Equity of  
8 health workforce distribution in Thailand: an implication of concentration index. *Risk Manag*  
9 *Healthc Policy*. 2019;12:13-22.
- 10 33. Ruamviboonsuk P, Krause J, Chotcomwongse P, Sayres R, Raman R, Widner K, et al. Deep  
11 learning versus human graders for classifying diabetic retinopathy severity in a nationwide  
12 screening program. *npj Digit Med*. 2019; 2(25).
- 13 34. Ong-ajyooth L, Vareesangthip K, Khonputsu P, Aekplakorn W. Prevalence of chronic kidney  
14 disease in Thai adults: a national health survey. *BMC Nephrol*. 2009; 10(35).
- 15 36. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupaijit K, Panpuwong N, et al.  
16 Cost of diabetes and its complications in Thailand: a complete picture of economic burden. *Health*  
17 *Soc Care Community*. 2011; 19(3), 289–298.

#### 18 Reports

- 19 30. Chittinan A, Eiam-ong S, Kantachuesiri S, Chailimpamontri W. Clinical Practice  
20 Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults 2015.  
21 1<sup>st</sup> ed. Bangkok: The Nephrology Society of Thailand; 2015. [cited 2020 Jan 10]. Available from:  
22 [http://www.nephrothai.org/images/10-11-](http://www.nephrothai.org/images/10-11-2016/Final_%E0%B8%84%E0%B8%A1%E0%B8%AD_CKD_2015.pdf)  
23 [2016/Final\\_%E0%B8%84%E0%B8%A1%E0%B8%AD\\_CKD\\_2015.pdf](http://www.nephrothai.org/images/10-11-2016/Final_%E0%B8%84%E0%B8%A1%E0%B8%AD_CKD_2015.pdf)
- 24 35. National Statistical Office, Kingdom of Thailand. The 2010 Population and Housing Census.  
25 Bangkok: National Statistical Office; 2012.

26  
27 22) *Do the authors have ideas about what could explain the disparities between males and females?*

28  
29 Thank you very much for your important observation. We added the explanations for the sex disparities  
30 as well as a caution to interpret them in Discussion section as follows.

31  
32 “Biology might play a part in observed sex differences as women typically transition from prediabetes  
33 to diabetes with a worse cardiovascular risk profile and a higher BMI than men. However, psychosocial  
34 factors, such as health-seeking behavior and provision of health care, play more important part in the  
35 differences, which can be addressed through changes in policy and health-care delivery [22]. It should  
36 be noted that high admission rate does not necessarily mean high prevalence of the disease, as previous  
37 studies showed higher percentage of undiagnosed diabetes [2] and slightly higher fasting plasma  
38 glucose among males in Thailand [23]” (Discussion, page 19, lines 11-17)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

23) *The authors are writing about HbA1c in prevention of CKD. I think it might be relevant to give more details about this point (for example, what is used in Thailand nowadays and why HbA1c would be better for CKD particularly).*

We appreciate your clarification. HbA1c is in fact recommended to be practiced regularly in prevention of CKD among people with diabetes in Thailand, although it has not been fully executed. Therefore, we have revised and added some information to the discussion section as follows.

“To prevent progression of CKD stage, the country should strengthen an effective measure, such as glycated hemoglobin control (HbA1c)  $\leq 7.0\%$  [21], as instructed in the Clinical Practice Recommendation for the Evaluation and Management of Chronic Kidney Disease in Adults 2015 [30].” (Discussion, page 21, lines 9-12)

24) *Since diabetes is an ambulatory disease, can the authors give us a sense of the burden in the community in Thailand? If not, please refer to other countries.*

Thank you very much for your suggestion. We have added information addressing a sense of burden in the community in Thailand as follows.

“Besides, community involvement in diabetic care should also be carefully monitored, as approximately 77.0% of cost is involved in non-medical activities [36], and community-based screening, study and health promotion would be increasingly important for diabetic care [4].” (Discussion, page 23, lines 15-18)

#### **Minor comments**

##### **Introduction**

25) *First sentence, please add “in the world.”*

Thank you very much for your suggestion. We assume the sentence starting with “globally” describes the situation “in the world”, but we changed “globally” to “in the world” to make the sentence clearer.

26) *P.4, 2nd paragraph: review the units for fasting glucose levels (130/dL).*

Thank you very much for correcting it. We have revised the unit from (130/dL) to (130mg/dL).

##### **Methods**

27) *I would specify the nature of the study: Retrospective study.*

1

2 Thank you very much for your suggestion. We have added the word, “retrospective data” in our  
3 manuscript as shown below.

4

5 “Descriptive analyses using the retrospective data were performed to summarize age, sex and regional  
6 structure of the UCS patients who were admitted for T2DM between 2009 and 2016 in Thailand and  
7 the trends in 2009 and 2016 were compared to depict the change in the trends over the eight years.”  
8 (Materials and methods: Data analysis, page 10, lines 5-7)

9

10 28) *Why the approbation of the study was done in Japan?*

11

12 Thank you very much for your enquiry. This is a study on Thailand, but the approbation was done in  
13 Japan because this is a Thai-Japan collaborative study based on the agreements made by the both  
14 national organizations.

15

16 **Results**

17 29) *Please correct everywhere women to females and men to males since you have administrative  
18 data and not information about gender.*

19

20 We appreciate your suggestion. We have corrected all the words “men and women” to “males and  
21 females” following your suggestion.


22

23 30) *Figure 4 would be easier to understand without the grey lines if you still present regional data.*

24

25 Thank you for pointing it out. We assume that “the grey lines”  
26 you mentioned are the ones shown on the right. These lines  
27 appear on some computers, but not all. In fact, we do not see the  
28 lines on our computers. We hope the editor has a technical means  
29 to solve this problem.

Type 2 diabetes mellitus (T2DM)



31 **Response to Reviewer #2**

32 **General comments:**

33 *The authors extract for the universal coverage scheme data all hospitalizations with diabetes listed  
34 among the primary or secondary diagnoses (to study admissions caused by diabetes-related  
35 complications) in the period 2009-2016. The impressively large and detailed dataset covers over 1.4  
36 million Thai age 15-100 and their 4.2 million admissions for type-2 diabetes (T2DM). They provide  
37 descriptive summaries, focusing on admission rates trends nationally and by region, for T2DM and*

1 major complications. The results show that standardizing for age and sex reduces the increasing trend  
2 in admission rates, suggesting that trends in population growth and aging are important determinants.

3  
4 **Specific comments:**

5 1) *Moreover, the authors speculate that the increase in elderly patients could be explained by*  
6 *greater longevity (i.e. reduced premature mortality) among DM patients. What does a life table*  
7 *for Thailand say about life expectancy conditional on surviving to age 50? 60? Is the growth rate*  
8 *in admissions comparable to the growth rate of survival at those ages? This could provide*  
9 *suggestive evidence confirming or refuting the authors' hypothesis.*

10  
11 We have stated in our manuscript that “the increased trend in T2DM admission rates was rather gradual  
12 as compared with the number of patients and admissions.” This means that the increase in the T2DM  
13 admission rates was partly influenced by the increased and aged population of the country, while there  
14 were also other reasons behind. To avoid this unclarity, we have added values of “sex-and age-adjusted  
15 T2DM admission rates”, and changed the word, “largely” to “partly” in the sentence as shown below.

16  
17 “While the number of patients, the number of admissions and admission rates of T2DM steadily  
18 increased from 2009 to 2016, the increased trend in the sex-and age-adjusted T2DM admission rates,  
19 which were estimated using the national UCS population of 2009 as the standard population, (12.1 in  
20 2009 and 15.0 in 2016, results not shown) were rather gradual as compared with the numbers of crude  
21 admissions rates (12.1 in 2009 and 17.3 in 2016). This result suggests that the increase in the T2DM  
22 admission rates is partly due to the increased and aged population of the country. Although further  
23 studies are required, it could imply that Thailand may face the greater burden of T2DM in the future if  
24 the trend of population growth and aging continues in the country.” (Discussion, page 20, line 1-8)

25  
26 2) *Of particular note is the high and rising trend in admissions for chronic kidney disease.*  
27 *Unfortunately, the authors do not have any proxies for resource use, but could estimate, based*  
28 *on some estimate of average length of stay and average charges per diem, the associated total*  
29 *spending and out-of-pocket burden. Admittedly that might constitute a separate paper, but it*  
30 *would provide important additional evidence for prioritizing policy to address inequalities of*  
31 *health and access.*

32  
33 Thank you so much for your brilliant suggestion. We'll work on this issue in our next research.

34  
35 3) *The authors do not discuss gestational diabetes, but that could account for some of the young*  
36 *adult female hospitalizations with diabetes especially as a secondary code and, unless the*  
37 *authors were sure the ICD10/9 codes used excluded them, merit discussion as a sub-category.*


1 Thank you very much for your sensible inquiry. However, we did not include gestational diabetes (ICD-  
2 10 code O24) in our study as described in the manuscript (please see below).

3  
4 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9),  
5 with or without CKD (N18.1 to N18.6, N18.9, E11.2, E14.2, N08.3, N19 and N18.9), MI (I21 and I22),  
6 cerebrovascular diseases (I60 to I69), retinopathy (H36.0), cataract (H25.0 to H25.2, H25.8, H25.9,  
7 H26.0 to H26.4, H26.8, H26.9, and H28.0), or diabetic foot amputations (8410-8417) were included,  
8 and any other cases were excluded from this study.” (Materials and methods: Definitions of T2DM and  
9 its complications, page 9, lines 9-14)

10  
11 4) *What are all the lines coming out of the graphs to the northwest in Figure 4? Fig 4. Comparisons*  
12 *of age- and sex- standardized admission ratios of type 2 diabetes mellitus and its complications*  
13 *in NHSO regions in 2009 and 2016*

14  
15 Thank you very much again. We assume that “the lines coming  
16 out of the graphs to the northwest” are the ones shown on the  
17 right. These lines appear on some computers, but not all. In fact,  
18 we do not see the lines on our computers. We hope the editor has  
19 a technical means to solve this problem.

Type 2 diabetes mellitus (T2DM)



20  
21 5) *Other explorations of the data that might be meaningful*  
22 *include correlation of the SAR with the % urban residents*  
23 *and/or per capita GDP and/or average years of schooling in each region; reporting and*  
24 *discussing the proportion of admissions in primary, secondary, and tertiary hospitals; at urban*  
25 *versus rural hospitals; at government vs private hospitals; at teaching hospitals vs non-teaching*  
26 *hospitals.*

27  
28 We appreciate your important suggestions. We revised the explanation of the geographical inequalities  
29 in Discussion section with the available data, as shown below.

30  
31 “On the other hand, the persistently high SAR of T2DM with retinopathy in Bangkok is presumably  
32 due to high density of specialists as half of 1,500 ophthalmologists, including 200 retinal specialists,  
33 practice in Bangkok [33].

34  
35 The persistently high SAR of T2DM with CKD in northeastern regions was consistent with a previous  
36 study and partly attributed to high prevalence of CKD in northeastern regions (10.8%) relative to other  
37 regions (north 8.9%, south 8.1% and Bangkok 6.2%) [34], but partly to an association with lower  
38 density of physicians and rurality of the region [13]. The density of physicians in northeastern regions

1 is the lowest in the country [32], as low as seven times lower than Bangkok [9]. It is reasonable to  
2 assume that in a region where physicians are scarce, T2DM patients with CKD are unlikely to receive  
3 timely, thorough and effective treatment, and consequently deteriorate in conditions. This assumption  
4 might explain the high readmission rates of T2DM with CDK, and the highest mortality rates due to  
5 diabetes in northeastern regions as found in another study [12]. Moreover, rurality of the northeastern  
6 regions, where 71.0% of the population reside in rural setting (north 65.6%, south 66.5% and Central  
7 54.5%) [35], might have halted them from accessing adequate primary care. A previous study found a  
8 strong association between the high SAR of diabetes and rurality as the rural population tends to have  
9 lack of public transport alternatives and poor health literacy with less education which often limit  
10 accessibility to health care. The study also suggested that the percentage of patients who had received  
11 up to secondary education was lower in rural districts by approximately 10% [13].” (Discussions, page  
12 22 line 10 to page 23, line 9)

13  
14 6) *To make the analyses comparable internationally and to allow even more precision in*  
15 *benchmarking the Thai national and regional trends in DM admissions, the authors could*  
16 *calculate the DM avoidable admissions rate as used in OECD metrics for the quality of primary*  
17 *care. This would simply involve standardizing to a comparable population, such as what the*  
18 *OECD does: rates per 100 000 population, age-sex standardized to the 2010 OECD population*  
19 *aged 15 and over (see references below). It would also provide an internationally comparable*  
20 *metric for benchmarking the Thai primary care system for DM management with other health*  
21 *systems, over the study period and as a baseline for tracking further improvements into the future.*  
22 *Of course, the authors may not be able to apply the full inclusion and exclusion criteria, so it*  
23 *would only be suggestive. For example, it does not seem that the authors can categorize the*  
24 *admissions according to whether or not the patient died during the admission. They may not be*  
25 *able to exclude those transferred from another hospital, although the date(s) of admission would*  
26 *be suggestive for creating that categorization from the raw admissions data. Again, estimating*  
27 *DM avoidable admissions rates could constitute a separate paper, but since it draws on exactly*  
28 *the kind of data the authors summarize in this paper, I would urge the authors to consider*  
29 *including this and thus able to attract a wider readership and evidence for policy top address the*  
30 *important trends they highlight.*

31  
32 We appreciate your sensible suggestion. We'll work on these in our next research.

### 34 **Response to Reviewer #3**

#### 35 **General comments:**

36 *This is an interesting manuscript providing the big picture of type 2 diabetes in the Thailand population*  
37 *between 2009-2016. I appreciated the reading and the figures are well-chosen. The authors conclude*  
38 *to an increase in type 2 diabetes over time. There may be a need for improved health care*

1 *system/policies/services/prevention for this population. Even though I appreciated the paper, I would*  
2 *have some questions for the authors.*

3  
4 **Major comments**

5 1) *Aren't there any paper published with those databases to support what the authors claim in the*  
6 *data section of the Method?*

7  
8 Thank you very much for your inquiry. As you suggested, we have included the following reference  
9 papers to support our decision to use only the data of 2009 and onwards in Materials and methods: Data  
10 section.

11  
12 1. Komwong D, Sriratanaban J. Association between Structures and resources of primary care at the  
13 district level and health outcomes: a case study of diabetes mellitus care in Thailand. Risk Manag  
14 Healthc Policy. 2018; 11, 199-208

15 2. Liabsuetrakul T, Sukmanee J, Thungthong J, Lumbiganon P. Trend of Cesarean Section Rates and  
16 Correlations with Advance Maternal and Nesecondary analysis of Thai Universal Coerage Scheme  
17 Data. AJP Rep. 2019; 9(4): 328-336.

18  
19 2) *Definitions of T2DM: where was diabetic amputation (only) defined based on the ICD 9 coding*  
20 *(paralele database?)?*

21  
22 We appreciate your concern. Diabetic amputation defined based on ICD-9 codes was a parallel database,  
23 “the operation database,” as described below, but the operation database also belongs to the National  
24 Health Security Office.

25  
26 “Two are reports sent from hospitals to the Ministry of Public Health, namely the hospital admission  
27 database and the operation database...” (Materials and methods: Data, page 8, lines 3-5)

28  
29 3) *I think there is a typo for the stroke definition (I60 to I69 and not I6.0 to I6.9). Furthermore, if*  
30 *those are really the codes used, it does not only refer to stroke but rather largely to*  
31 *cerebrovascular diseases.*

32  
33 Thank you very much for pointing it out. We have corrected the text as follows:

34  
35 “All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9)  
36 ...cerebrovascular diseases (I60 to I69), ...” (Materials and methods: Definitions of T2DM and its  
37 complications, page 9, lines 9-11)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

According to your suggestion, we also corrected the word “stroke” to “cerebrovascular diseases.”

4) *Diabetic amputations codes selection (ICD9 8401-8415) would need a reference or more explanations for rational.*

We appreciate your suggestion. We have carefully reviewed ICD-9 codes again and slightly changed the codes included this study and revised the text as follows.

“All UCS admitted cases whose principal or secondary diagnosis were coded as T2DM (E11.1 to E11.9), with or without ... or diabetic foot amputations (8410-8417) were included ... Diagnosis of foot amputation was considered as a diabetic complication if it was performed from the toe to above the knee.” (Materials and methods: Definitions of T2DM and its complications, page 9, line 9 to page 10, line 2)

5) *Data analysis: the authors should explain how were the 2009-2016 trends compared (visually I think).*

Thank you very much for your important suggestion. Please see Fig. 3 that explains the 2009-2016 trends visually.

6) *The results would benefit from a more sophisticated trend analysis, using for example a binomial regression model to obtain the precise slope % and a contrast test to compare in sub-analyses. Even though different, this paper and its references may help: Leclerc J et al. Circulation: Cardiovascular Quality and Outcomes, 2017.*

We very much appreciated your proposal with the useful reference for a more sophisticated trend analysis. We have conducted time series regressions with the following negative binomial regression model, and added the methods and results to our manuscript as shown below.

“To estimate temporal trend of admissions, we conducted time series regressions with the following negative binomial regression model.

$$n_i \sim \text{NegativeBinomial}(\mu_i, \phi)$$

$$\mu_i = \exp(\beta_0 + \beta_1 x + \log N_i)$$

where  $n_i$  is the number of admissions of  $i$ th time point,  $N_i$  is the number of UC population of  $i$ th time point,  $x$  is the indicator variable of time points,  $\mu$  is the mean parameter and  $\phi$  is dispersion parameter of Negative Binomial distribution,  $\beta_0$  is the intercept, and  $\beta_1$  is the slope parameter.”

(Materials and methods: Data analyses, page 11, line 1 - 5)

1  
 2 “Table 2 presents the results of the time series regressions to estimate temporal trend of admissions  
 3 showed that all types of T2DM admissions except that with cataract had a significant and positive  
 4 temporal trend.

5

6 **Table 2. Time series regressions parameters of temporal trend analysis for admissions**

| Parameters                                  | Estimate  | SE       | z value  | p value   |
|---|-----------|----------|----------|-----------|
| All DM admissions                           |           |          |          |           |
| $\beta_0$ : intercept                       | -4.460529 | 0.006002 | -743.16  | p < 0.001 |
| $\beta_1$ : time point                      | 0.050566  | 0.001187 | 42.61    | p < 0.001 |
| DM with CKD admissions                      |           |          |          |           |
| $\beta_0$ : intercept                       | -6.108389 | 0.009446 | -646.64  | p < 0.001 |
| $\beta_1$ : time point                      | 0.095675  | 0.001861 | 51.41    | p < 0.001 |
| DM with MI admissions                       |           |          |          |           |
| $\beta_0$ : intercept                       | -8.11538  | 0.02155  | -376.58  | p < 0.001 |
| $\beta_1$ : time point                      | 0.07541   | 0.00424  | 17.78    | p < 0.001 |
| DM with cerebrovascular diseases admissions |           |          |          |           |
| $\beta_0$ : intercept                       | -7.251687 | 0.009935 | -729.93  | p < 0.001 |
| $\beta_1$ : time point                      | 0.084358  | 0.001941 | 43.47    | p < 0.001 |
| DM with cataract admissions                 |           |          |          |           |
| $\beta_0$ : intercept                       | -7.604557 | 0.046891 | -162.175 | p < 0.001 |
| $\beta_1$ : time point                      | 0.015244  | 0.009283 | 1.642    | 0.101     |
| DM with retinopathy admissions              |           |          |          |           |
| $\beta_0$ : intercept                       | -8.941096 | 0.028458 | -314.181 | p < 0.001 |
| $\beta_1$ : time point                      | 0.049766  | 0.005599 | 8.888    | p < 0.001 |
| DM with amputation admissions               |           |          |          |           |
| $\beta_0$ : intercept                       | -8.955374 | 0.023377 | -383.09  | p < 0.001 |
| $\beta_1$ : time point                      | 0.050946  | 0.004584 | 11.12    | p < 0.001 |

7 Note: SE: Standard error, CI: Confidence interval, DM: Diabetes mellitus, CKD: Chronic kidney  
 8 disease, MI: Myocardial infarction  
 9 (Results, page 16, line 9 to page 17, line 2)

10

1 7) *Was the age and sex distribution of the population in 2009 ever published? If so, a reference*  
2 *would be needed in the data analysis section.*

3  
4 Thank you so much for your inquiry. We are afraid the age and sex distribution of the UCS population  
5 in 2009 has not been published. The data of UCS population of 2009 we used was provided by the  
6 National Health Security Office (NHSO), Thailand.

7  
8 as the standard for age- and sex-adjustment.

9  
10 8) *"the expected number of admissions in region": please provide more details (ex.: according to*  
11 *the literature, the country level of admission, etc.)*

12  
13 We appreciate your enquiry. "The expected number of admissions in region" is explained as follows in  
14 Materials and methods: Data analysis section.

15  
16 "We estimated the standardized admission ratio (SAR) of each region using the following equation for  
17 each region.

$$SAR_i = \frac{o_i}{e_i}$$

$$e_i = \sum_{j=1}^J p_j n_{ij}$$

18  
19  
20 where SAR<sub>i</sub> is standardized admission ratio in region i; o<sub>i</sub> is the observed number of admissions in  
21 region i; e<sub>i</sub> is the expected number of admissions in region i; j is the population stratum defined by age  
22 and sex; p<sub>j</sub> is standard admission rate in the 2009 UCS population for the population stratum j."  
23 (Materials and methods: Data analysis, page 10, lines 9-15)

24  
25 9) *"Age was categorize into 15 groups of five-year intervals" is not fully accurate, and the last*  
26 *category is 85 to 100 years old. This should be adjusted.*

27  
28 Thank you so much for pointing it out. We have corrected the sentence as shown below and changed  
29 the value labels from "85+" to "85-100" in figures and tables.

30  
31 "Age was categorized into 15 groups in intervals of five years, except the last category that includes 85  
32 to 100 years of age" (Materials and methods: Data analysis, page 10, lines 16-17)

33  
34 **Minor comments:**

35 10) *Fig 3, "cases with amputation" should be written "amputation"*


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

Thank you for pointing it out. We corrected the word in the figure.

11) *Fig 4, this would be beautiful without all the diagonals accross the pictures. Any way to remove it?*

Thank you very much again. We assume that “the diagonals across the pictures” are the ones shown on the right. These lines appear on some computers, but not all. In fact, we did not see the lines on our computers. We hope the editor has a technical means to solve this problem.

Type 2 diabetes mellitus (T2DM)



**Additional editor comments:**

**Journal requirements:**

1) *Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.*

Thank you very much for your kind advice with useful URLs. We have carefully revised our manuscript in accordance with the PLOS ONE style.

2) *In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. Moreover, in you Data statement, please ensure that it is clear how you obtained the data, and how other researchers can request access to the same database.*

Thank you very much for bringing out this issue. We obtained the data in the National Health Security Office which manages the database as the first author belongs to the organization. However, we added the sentence clarifying that all data were anonymous, as shown below. We also added the information of how others can access to the database in the “Data reporting” section, as follows.

“All data were fully anonymized before we accessed them.” (Materials and methods: Data, page 8, lines 8-9)

1 “All patient records were fully anonymized before we accessed. The relevant UCS data are available  
2 upon request to the National Health Security Office, Thailand, with the research outline and the details  
3 of the required data.” (Data reporting, page 25, lines 15-17)

4  
5 3) *Our internal editors have looked over your manuscript and determined that it is within the scope  
6 of our Health Inequities and Disparities Research Call for Papers. If you would like your  
7 manuscript to be considered for this collection, please let us know in your cover letter and we  
8 will ensure that your paper is treated as if you were responding to this call. If you would prefer  
9 to remove your manuscript from collection consideration, please specify this in the cover letter.*

10 Thank you very much for inviting us to the special research call. As indicated in the cover letter, we  
11 would like our manuscript to be considered for this collection.

12 4) *We note that you have indicated that data from this study are available upon request. In your  
13 revised cover letter, please address the following prompts:*

14 a) *If there are ethical or legal restrictions on sharing a de-identified data set, please explain  
15 them in detail (e.g., data contain potentially identifying or sensitive patient information) and  
16 who has imposed them (e.g., an ethics committee). Please also provide contact information  
17 for a data access committee, ethics committee, or other institutional body to which data  
18 requests may be sent.*

19 b) *If there are no restrictions, please upload the minimal anonymized data set necessary to  
20 replicate your study findings as either Supporting Information files or to a stable, public  
21 repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see  
22 <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and  
23 prepare clinical data for publication. For a list of acceptable repositories, please see  
24 <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.*

25 Thank you very much for pointing this out. The National Health Security Office (NHSO) follows the  
26 Information Security Policy, Information Security Management System procedure (QP-407 10-001).  
27 An individual who wishes to use the UCS databases must sign the Non-Disclosure Agreement (NDA)  
28 with NHSO, and submit copies of documents, reports, articles or publications that use the data. The use  
29 of the data is restricted within the research framework and the person should be responsible for his/her  
30 own actions in case of a lawsuit, etc. We have added the information to the revised cover letter.

31 5) *PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers  
32 submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is  
33 validated in Editorial Manager.*

1 The corresponding author checked it and he ensured that the ORCID iD was validated in Editorial  
2 Manager.

3 6) *Your ethics statement must appear in the Methods section of your manuscript. Please also ensure*  
4 *that your ethics statement is included in your manuscript, as the ethics section of your online*  
5 *submission will not be published alongside your manuscript.*  
6

7 Thank you very much for your kind reminder. We have added the ethics statement in the Methods  
8 section as shown below.

9  
10 “Ethics of the study was approved by the Institutional Review Board of the National Center for Global  
11 Health and Medicine (NCGM) in Japan on 11 May 2018 (NCGM-G-002524-00).” (Materials and  
12 methods: Data analyses, page 11, lines 11-12)  
13

14 7) *We note that Figure 4 in your submission contains map images which may be copyrighted. We*  
15 *require you to either (1) present written permission from the copyright holder to publish these*  
16 *figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission.*  
17

18 We have created the map images with the geodatabase retrieved from the website, the Humanitarian  
19 Development Exchange (HDX). As far as our understanding, all the databases offered under the CC  
20 BY license are free to share and or adapt for any purpose, even commercially. It is also stated that no  
21 one can apply legal terms or technological measures that legally restrict others from doing anything the  
22 license permits (please see the website from <https://data.humdata.org/about/license>).  
23

24 If there are any problem about license of the map images, please let us know.  
25

26 8) *Please upload a copy of Supporting Information Table 1 and 2, which you refer to in your text on*  
27 *page 14.*  
28

29 Thank you very much for your concern. We finally decided not to include Supplementary table 1 and  
30 2, but missed deleting the sentence which indicates the Supplementary tables in the manuscript. This  
31 time, we deleted the sentence.